WO2009023718A2 - Novel activators of glucokinase - Google Patents
Novel activators of glucokinase Download PDFInfo
- Publication number
- WO2009023718A2 WO2009023718A2 PCT/US2008/073026 US2008073026W WO2009023718A2 WO 2009023718 A2 WO2009023718 A2 WO 2009023718A2 US 2008073026 W US2008073026 W US 2008073026W WO 2009023718 A2 WO2009023718 A2 WO 2009023718A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- alkyl
- och
- group
- aryl
- Prior art date
Links
- 239000012190 activator Substances 0.000 title abstract description 5
- 102000030595 Glucokinase Human genes 0.000 title description 12
- 108010021582 Glucokinase Proteins 0.000 title description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 287
- 238000000034 method Methods 0.000 claims abstract description 108
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 45
- 201000010099 disease Diseases 0.000 claims abstract description 41
- 150000003839 salts Chemical class 0.000 claims abstract description 29
- 238000011161 development Methods 0.000 claims abstract description 26
- 201000001421 hyperglycemia Diseases 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 208000002705 Glucose Intolerance Diseases 0.000 claims abstract description 14
- 201000009104 prediabetes syndrome Diseases 0.000 claims abstract description 13
- 239000013078 crystal Substances 0.000 claims abstract description 11
- 229940124828 glucokinase activator Drugs 0.000 claims abstract description 6
- -1 substituted Chemical class 0.000 claims description 467
- 125000000217 alkyl group Chemical group 0.000 claims description 338
- 125000001072 heteroaryl group Chemical group 0.000 claims description 221
- 125000004429 atom Chemical group 0.000 claims description 219
- 125000003118 aryl group Chemical group 0.000 claims description 207
- 229910052721 tungsten Inorganic materials 0.000 claims description 159
- 125000004122 cyclic group Chemical group 0.000 claims description 157
- 229910052799 carbon Inorganic materials 0.000 claims description 129
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 126
- 229910052739 hydrogen Inorganic materials 0.000 claims description 124
- 239000001257 hydrogen Substances 0.000 claims description 122
- 125000001424 substituent group Chemical group 0.000 claims description 118
- 229910052736 halogen Inorganic materials 0.000 claims description 113
- 150000002367 halogens Chemical class 0.000 claims description 113
- 125000003107 substituted aryl group Chemical group 0.000 claims description 108
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 105
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 104
- 125000005549 heteroarylene group Chemical group 0.000 claims description 99
- 125000005842 heteroatom Chemical group 0.000 claims description 83
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 81
- 125000004432 carbon atom Chemical group C* 0.000 claims description 80
- 239000000651 prodrug Substances 0.000 claims description 79
- 229940002612 prodrug Drugs 0.000 claims description 79
- 125000002947 alkylene group Chemical group 0.000 claims description 75
- 150000002431 hydrogen Chemical group 0.000 claims description 74
- 229910052727 yttrium Inorganic materials 0.000 claims description 70
- 229910052720 vanadium Inorganic materials 0.000 claims description 68
- 125000003545 alkoxy group Chemical group 0.000 claims description 67
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 57
- 229910052717 sulfur Inorganic materials 0.000 claims description 56
- 229910052760 oxygen Inorganic materials 0.000 claims description 55
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 48
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 48
- 125000004104 aryloxy group Chemical group 0.000 claims description 45
- 229910052757 nitrogen Inorganic materials 0.000 claims description 43
- 125000000732 arylene group Chemical group 0.000 claims description 39
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 35
- 125000006413 ring segment Chemical group 0.000 claims description 35
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 34
- 150000001721 carbon Chemical group 0.000 claims description 30
- 229910052698 phosphorus Inorganic materials 0.000 claims description 28
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 27
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 26
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 26
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 26
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 26
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 25
- 239000011574 phosphorus Substances 0.000 claims description 25
- 125000004423 acyloxy group Chemical group 0.000 claims description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 22
- 241001465754 Metazoa Species 0.000 claims description 22
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims description 22
- 239000008103 glucose Substances 0.000 claims description 22
- 125000002252 acyl group Chemical group 0.000 claims description 19
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims description 19
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 claims description 18
- 125000005205 alkoxycarbonyloxyalkyl group Chemical group 0.000 claims description 17
- 125000005750 substituted cyclic group Chemical group 0.000 claims description 17
- 125000000335 thiazolyl group Chemical group 0.000 claims description 17
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 16
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 16
- 125000000304 alkynyl group Chemical group 0.000 claims description 15
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims description 13
- 229910018828 PO3H2 Inorganic materials 0.000 claims description 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 13
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 13
- 125000004434 sulfur atom Chemical group 0.000 claims description 13
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 13
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims description 11
- 125000004450 alkenylene group Chemical group 0.000 claims description 11
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims description 11
- 125000005110 aryl thio group Chemical group 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- 206010022489 Insulin Resistance Diseases 0.000 claims description 9
- 230000002440 hepatic effect Effects 0.000 claims description 9
- 125000001544 thienyl group Chemical group 0.000 claims description 9
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 8
- 125000004419 alkynylene group Chemical group 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 8
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 8
- 125000004659 aryl alkyl thio group Chemical group 0.000 claims description 7
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 7
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 7
- 125000005368 heteroarylthio group Chemical group 0.000 claims description 7
- 125000002883 imidazolyl group Chemical group 0.000 claims description 7
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 7
- 125000002971 oxazolyl group Chemical group 0.000 claims description 7
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 7
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 6
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 6
- 125000005366 cycloalkylthio group Chemical group 0.000 claims description 6
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 claims description 5
- 208000011661 metabolic syndrome X Diseases 0.000 claims description 5
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 4
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 4
- 201000008980 hyperinsulinism Diseases 0.000 claims description 4
- 230000004110 gluconeogenesis Effects 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 41
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 30
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 19
- 102000004877 Insulin Human genes 0.000 abstract description 15
- 108090001061 Insulin Proteins 0.000 abstract description 15
- 229940125396 insulin Drugs 0.000 abstract description 15
- 230000008569 process Effects 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 description 46
- 238000003786 synthesis reaction Methods 0.000 description 42
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 35
- 239000003814 drug Substances 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 30
- 229940079593 drug Drugs 0.000 description 28
- 239000002253 acid Substances 0.000 description 26
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 22
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 22
- 229960001031 glucose Drugs 0.000 description 22
- 238000005859 coupling reaction Methods 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 21
- 150000002148 esters Chemical class 0.000 description 20
- 238000009472 formulation Methods 0.000 description 20
- 239000010410 layer Substances 0.000 description 20
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 19
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 16
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 235000019439 ethyl acetate Nutrition 0.000 description 15
- 150000003009 phosphonic acids Chemical class 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 229910001868 water Inorganic materials 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
- 238000009434 installation Methods 0.000 description 14
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 14
- 230000008878 coupling Effects 0.000 description 12
- 238000010168 coupling process Methods 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 11
- 238000006722 reduction reaction Methods 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 10
- 150000007513 acids Chemical class 0.000 description 10
- 238000007792 addition Methods 0.000 description 10
- 238000005755 formation reaction Methods 0.000 description 10
- 230000003914 insulin secretion Effects 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000002877 alkyl aryl group Chemical group 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 238000010511 deprotection reaction Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 230000029936 alkylation Effects 0.000 description 8
- 238000005804 alkylation reaction Methods 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000006073 displacement reaction Methods 0.000 description 8
- 125000000623 heterocyclic group Chemical group 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 7
- 238000013270 controlled release Methods 0.000 description 7
- 230000007062 hydrolysis Effects 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 6
- 229940035437 1,3-propanediol Drugs 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000006751 Mitsunobu reaction Methods 0.000 description 6
- 238000006619 Stille reaction Methods 0.000 description 6
- 238000006069 Suzuki reaction reaction Methods 0.000 description 6
- 125000004414 alkyl thio group Chemical group 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical group O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 5
- 239000007900 aqueous suspension Substances 0.000 description 5
- 125000001769 aryl amino group Chemical group 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000012320 chlorinating reagent Substances 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- RLMGYIOTPQVQJR-UHFFFAOYSA-N cyclohexane-1,3-diol Chemical compound OC1CCCC(O)C1 RLMGYIOTPQVQJR-UHFFFAOYSA-N 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 230000004190 glucose uptake Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- OTYNBGDFCPCPOU-UHFFFAOYSA-N phosphane sulfane Chemical compound S.P[H] OTYNBGDFCPCPOU-UHFFFAOYSA-N 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 125000004437 phosphorous atom Chemical group 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 4
- 238000003547 Friedel-Crafts alkylation reaction Methods 0.000 description 4
- 208000013016 Hypoglycemia Diseases 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 238000006411 Negishi coupling reaction Methods 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 125000002723 alicyclic group Chemical group 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 4
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 4
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 4
- 244000309464 bull Species 0.000 description 4
- 150000007942 carboxylates Chemical class 0.000 description 4
- 150000001733 carboxylic acid esters Chemical class 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 239000007859 condensation product Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 150000002009 diols Chemical class 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 125000004185 ester group Chemical group 0.000 description 4
- ROBXZHNBBCHEIQ-BYPYZUCNSA-N ethyl (2s)-2-aminopropanoate Chemical compound CCOC(=O)[C@H](C)N ROBXZHNBBCHEIQ-BYPYZUCNSA-N 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 238000007327 hydrogenolysis reaction Methods 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 229940086542 triethylamine Drugs 0.000 description 4
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 150000001502 aryl halides Chemical class 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 210000001217 buttock Anatomy 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000002359 drug metabolite Substances 0.000 description 3
- 239000012039 electrophile Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000009229 glucose formation Effects 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 3
- 150000002596 lactones Chemical class 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- DEBIRCCWRNLVFD-UHFFFAOYSA-N methyl 3-hydroxy-5-propan-2-yloxybenzoate Chemical compound COC(=O)C1=CC(O)=CC(OC(C)C)=C1 DEBIRCCWRNLVFD-UHFFFAOYSA-N 0.000 description 3
- JIFOUOVHDXMRQY-UHFFFAOYSA-N methyl 3-propan-2-yloxy-5-(2-thiophen-3-ylethoxy)benzoate Chemical compound CC(C)OC1=CC(C(=O)OC)=CC(OCCC2=CSC=C2)=C1 JIFOUOVHDXMRQY-UHFFFAOYSA-N 0.000 description 3
- RJNLZJWLXPMFCN-UHFFFAOYSA-N n-[5-[ethoxy(methyl)phosphoryl]pyridin-2-yl]-3-propan-2-yloxy-5-(2-thiophen-3-ylethoxy)benzamide Chemical compound N1=CC(P(C)(=O)OCC)=CC=C1NC(=O)C1=CC(OCCC2=CSC=C2)=CC(OC(C)C)=C1 RJNLZJWLXPMFCN-UHFFFAOYSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 239000001301 oxygen Chemical group 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 125000005541 phosphonamide group Chemical group 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- KYNFOMQIXZUKRK-UHFFFAOYSA-N 2,2'-dithiodiethanol Chemical compound OCCSSCCO KYNFOMQIXZUKRK-UHFFFAOYSA-N 0.000 description 2
- OHWMJHMSUDKMGL-UHFFFAOYSA-N 2-(hydroxymethyl)cyclohexan-1-ol Chemical class OCC1CCCCC1O OHWMJHMSUDKMGL-UHFFFAOYSA-N 0.000 description 2
- UADBLZFWTJHOJC-UHFFFAOYSA-N 2-(hydroxymethyl)cyclopentan-1-ol Chemical class OCC1CCCC1O UADBLZFWTJHOJC-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- BXOPNHUQVVADJE-UHFFFAOYSA-N 3-propan-2-yloxy-5-(2-thiophen-3-ylethoxy)benzoic acid Chemical compound OC(=O)C1=CC(OC(C)C)=CC(OCCC2=CSC=C2)=C1 BXOPNHUQVVADJE-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LQVXSNNAFNGRAH-QHCPKHFHSA-N BMS-754807 Chemical compound C([C@@]1(C)C(=O)NC=2C=NC(F)=CC=2)CCN1C(=NN1C=CC=C11)N=C1NC(=NN1)C=C1C1CC1 LQVXSNNAFNGRAH-QHCPKHFHSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 206010023379 Ketoacidosis Diseases 0.000 description 2
- 208000007976 Ketosis Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 238000005654 Michaelis-Arbuzov synthesis reaction Methods 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical class CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- 125000005354 acylalkyl group Chemical group 0.000 description 2
- 238000007259 addition reaction Methods 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 238000005575 aldol reaction Methods 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000010976 amide bond formation reaction Methods 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 150000003934 aromatic aldehydes Chemical class 0.000 description 2
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 2
- 150000007860 aryl ester derivatives Chemical class 0.000 description 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 125000005841 biaryl group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- WWDMDHUOYPEXQH-UHFFFAOYSA-N chloro(phenoxy)phosphinic acid Chemical compound OP(Cl)(=O)OC1=CC=CC=C1 WWDMDHUOYPEXQH-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 150000005676 cyclic carbonates Chemical class 0.000 description 2
- 150000001923 cyclic compounds Chemical class 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 238000007257 deesterification reaction Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 2
- NFORZJQPTUSMRL-UHFFFAOYSA-N dipropan-2-yl hydrogen phosphite Chemical compound CC(C)OP(O)OC(C)C NFORZJQPTUSMRL-UHFFFAOYSA-N 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000006735 epoxidation reaction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 230000010030 glucose lowering effect Effects 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000005343 heterocyclic alkyl group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000037323 metabolic rate Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- RNVFYQUEEMZKLR-UHFFFAOYSA-N methyl 3,5-dihydroxybenzoate Chemical compound COC(=O)C1=CC(O)=CC(O)=C1 RNVFYQUEEMZKLR-UHFFFAOYSA-N 0.000 description 2
- 229940102396 methyl bromide Drugs 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- 239000012053 oil suspension Substances 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 2
- 125000005633 phthalidyl group Chemical group 0.000 description 2
- 229950010765 pivalate Drugs 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000029537 positive regulation of insulin secretion Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 150000007944 thiolates Chemical class 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 238000005809 transesterification reaction Methods 0.000 description 2
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- SJHCUXCOGGKFAI-UHFFFAOYSA-N tripropan-2-yl phosphite Chemical compound CC(C)OP(OC(C)C)OC(C)C SJHCUXCOGGKFAI-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- PTNZGHXUZDHMIQ-CVHRZJFOSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-CVHRZJFOSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- FMTNMUJSOHIDRT-UHFFFAOYSA-N 1,3,2-dioxaphosphonane Chemical compound C1CCCOPOCC1 FMTNMUJSOHIDRT-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SFRDXVJWXWOTEW-UHFFFAOYSA-N 2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)CO SFRDXVJWXWOTEW-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- YYPNNBPPDFTQFX-UHFFFAOYSA-N 2-thiophen-3-ylethanol Chemical compound OCCC=1C=CSC=1 YYPNNBPPDFTQFX-UHFFFAOYSA-N 0.000 description 1
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 1
- RXMVFKJGHWRWCA-UHFFFAOYSA-N 2h-benzotriazol-4-yloxy-tris(dimethylamino)phosphanium Chemical class CN(C)[P+](N(C)C)(N(C)C)OC1=CC=CC2=C1N=NN2 RXMVFKJGHWRWCA-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- ULMZOZMSDIOZAF-UHFFFAOYSA-N 3-hydroxy-2-(hydroxymethyl)propanoic acid Chemical compound OCC(CO)C(O)=O ULMZOZMSDIOZAF-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- KBSDLBVPAHQCRY-UHFFFAOYSA-N 307496-19-1 Chemical group C1CC=CCC1CC[Si](O1)(O2)O[Si](O3)(C4CCCC4)O[Si](O4)(C5CCCC5)O[Si]1(C1CCCC1)O[Si](O1)(C5CCCC5)O[Si]2(C2CCCC2)O[Si]3(C2CCCC2)O[Si]41C1CCCC1 KBSDLBVPAHQCRY-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- DOAJGZPIIASLSO-UHFFFAOYSA-N C=1C=CC=CC=1OP(=O)OCC1=CC=CC=C1 Chemical class C=1C=CC=CC=1OP(=O)OCC1=CC=CC=C1 DOAJGZPIIASLSO-UHFFFAOYSA-N 0.000 description 1
- DEVWEFBXXYMHIL-UHFFFAOYSA-N CCCOP(O)=O Chemical compound CCCOP(O)=O DEVWEFBXXYMHIL-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- IVHVNMLJNASKHW-UHFFFAOYSA-M Chlorphonium chloride Chemical compound [Cl-].CCCC[P+](CCCC)(CCCC)CC1=CC=C(Cl)C=C1Cl IVHVNMLJNASKHW-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- 101100050026 Enterobacteria phage T4 y01J gene Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N Glycolaldehyde Chemical class OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000840558 Homo sapiens Hexokinase-4 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010052341 Impaired insulin secretion Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- WISFFURXZUXJPO-UHFFFAOYSA-N NP(=O)OC1=CC=CC=C1 Chemical class NP(=O)OC1=CC=CC=C1 WISFFURXZUXJPO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- LTBRACVJRXLQHC-UHFFFAOYSA-N OP(=O)OCC1=CC=CC=C1 Chemical class OP(=O)OCC1=CC=CC=C1 LTBRACVJRXLQHC-UHFFFAOYSA-N 0.000 description 1
- IGYZIZQEEZDUQY-UHFFFAOYSA-N OP(=O)O[SiH3] Chemical class OP(=O)O[SiH3] IGYZIZQEEZDUQY-UHFFFAOYSA-N 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 229910020667 PBr3 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 238000006202 Sharpless epoxidation reaction Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- AFCIMSXHQSIHQW-UHFFFAOYSA-N [O].[P] Chemical compound [O].[P] AFCIMSXHQSIHQW-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000007824 aliphatic compounds Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004171 alkoxy aryl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- GJYJYFHBOBUTBY-UHFFFAOYSA-N alpha-camphorene Chemical compound CC(C)=CCCC(=C)C1CCC(CCC=C(C)C)=CC1 GJYJYFHBOBUTBY-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940059260 amidate Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- OGBVRMYSNSKIEF-UHFFFAOYSA-L benzyl-dioxido-oxo-$l^{5}-phosphane Chemical compound [O-]P([O-])(=O)CC1=CC=CC=C1 OGBVRMYSNSKIEF-UHFFFAOYSA-L 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 150000005347 biaryls Chemical group 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- YSGHVVHSZCACTQ-UHFFFAOYSA-N bis(trimethylsilyloxy)phosphane Chemical compound C[Si](C)(C)OPO[Si](C)(C)C YSGHVVHSZCACTQ-UHFFFAOYSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 230000025938 carbohydrate utilization Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- ITVPBBDAZKBMRP-UHFFFAOYSA-N chloro-dioxido-oxo-$l^{5}-phosphane;hydron Chemical compound OP(O)(Cl)=O ITVPBBDAZKBMRP-UHFFFAOYSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- FSDSKERRNURGGO-UHFFFAOYSA-N cyclohexane-1,3,5-triol Chemical class OC1CC(O)CC(O)C1 FSDSKERRNURGGO-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- KFGFLEOUNBSLSO-UHFFFAOYSA-N dioxaphosphonane Chemical compound C1CCCPOOCC1 KFGFLEOUNBSLSO-UHFFFAOYSA-N 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- AGWPTXYSXUNKLV-UHFFFAOYSA-N ethoxy-methyl-oxophosphanium Chemical compound CCO[P+](C)=O AGWPTXYSXUNKLV-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000006343 heptafluoro propyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229950011479 hyclate Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-M lactobionate Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-M 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-N methyl sulfate Chemical compound COS(O)(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- LYPCKRLNCZKHKE-UHFFFAOYSA-N methyl-[6-[[3-propan-2-yloxy-5-(2-thiophen-3-ylethoxy)benzoyl]amino]pyridin-3-yl]phosphinic acid Chemical compound C=1C(C(=O)NC=2N=CC(=CC=2)P(C)(O)=O)=CC(OC(C)C)=CC=1OCCC=1C=CSC=1 LYPCKRLNCZKHKE-UHFFFAOYSA-N 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- KZFPOYJOTNBBJN-UHFFFAOYSA-N n-(5-bromopyridin-2-yl)-3-propan-2-yloxy-5-(2-thiophen-3-ylethoxy)benzamide Chemical compound C=1C(C(=O)NC=2N=CC(Br)=CC=2)=CC(OC(C)C)=CC=1OCCC=1C=CSC=1 KZFPOYJOTNBBJN-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- ZCYXXKJEDCHMGH-UHFFFAOYSA-N nonane Chemical compound CCCC[CH]CCCC ZCYXXKJEDCHMGH-UHFFFAOYSA-N 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- BKIMMITUMNQMOS-UHFFFAOYSA-N normal nonane Natural products CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 230000009996 pancreatic endocrine effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 150000004686 pentahydrates Chemical class 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 125000006187 phenyl benzyl group Chemical group 0.000 description 1
- XNQULTQRGBXLIA-UHFFFAOYSA-O phosphonic anhydride Chemical compound O[P+](O)=O XNQULTQRGBXLIA-UHFFFAOYSA-O 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical class CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical group CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000006462 rearrangement reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000006894 reductive elimination reaction Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- FOEYMRPOKBCNCR-UHFFFAOYSA-N spiro[2.5]octane Chemical compound C1CC11CCCCC1 FOEYMRPOKBCNCR-UHFFFAOYSA-N 0.000 description 1
- VMWOETMUNAQFAX-UHFFFAOYSA-N spiro[3.5]nonane Chemical compound C1CCC21CCCCC2 VMWOETMUNAQFAX-UHFFFAOYSA-N 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 125000004014 thioethyl group Chemical group [H]SC([H])([H])C([H])([H])* 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 150000004072 triols Chemical class 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
- C07F9/6541—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3834—Aromatic acids (P-C aromatic linkage)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4021—Esters of aromatic acids (P-C aromatic linkage)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/653—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
- C07F9/65392—Five-membered rings containing two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
- C07F9/65392—Five-membered rings containing two nitrogen atoms
- C07F9/65395—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
- C07F9/65392—Five-membered rings containing two nitrogen atoms
- C07F9/65397—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
- C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
Definitions
- the present invention is directed towards novel activators of glucokinase.
- the present invention relates to compounds and pharmaceutical compositions of Formulas I and II, including pharmaceutically acceptable salts or co-crystals, and prodrugs thereof which activate the enzyme glucokinase.
- the present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. Also provided are methods of making or manufacturing compounds of Formulas I and II and pharmaceutically acceptable salts or co-crystals, and prodrugs thereof.
- Acyl refers to -C(O)R S where R s is alkyl, heterocycloalkyl, or aryl.
- Acylalkyl refers to an alkyl-C(O)-alk-, wherein “alk” is alkylene.
- Acylamino refers to and R W C(O)-NR W -, wherein R w is -H, alkyl, aryl, aralkyl, and heterocycloalkyl.
- Acyloxy refers to the ester group -0-C(O)R 1 , where R 1 is H, alkyl, alkenyl, alkynyl, aryl, aralkyl, or heterocycloalkyl.
- Alicyclic refers to a cyclic group or compound which combines the properties of aliphatic and cyclic compounds and include but are not limited to cycloalkyl and bridged cycloalkyl compounds. The cyclic compound includes heterocycles. Cyclohexenylethyl, cyclohexanylethyl, and norbornyl are suitable alicyclic groups. Such groups may be optionally substituted.
- Alkanoyl refers to the group alkyl-C(O)-.
- Alkenyl refers to unsaturated groups which have 2 to 12 atoms and contain at least one carbon-carbon double bond and includes straight-chain, branched-chain and cyclic groups included alkenylene and alkynylene. Alkenyl groups may be optionally substituted. Suitable alkenyl groups include allyl. "1 -alkenyl” refers to alkenyl groups where the double bond is between the first and second carbon atom. If the 1 -alkenyl group is attached to another group, it is attached at the first carbon.
- Alkylaminoalkyl- refers to the group alkyl-NR u -alk- wherein each "alk” is an independently selected alkylene, and R u is H or lower alkyl.
- Lower alkylaminoalkyl- refers to groups where the alkyl and the alkylene group is lower alkyl and alkylene, respectively.
- Alkylaminoalkyl carboxy refers to the group alkyl-NR u -alk-C(O)-O- where "alk” is an alkylene group, and R u is a H or lower alkyl.
- Alkylaminoaryl- refers to the group alkyl-NR v -aryl- wherein “aryl” is a divalent group and R v is -H, alkyl, aralkyl, or heterocycloalkyl. In “lower alkylaminoaryl-”, the alkyl group is lower alkyl.
- Alkoxy- or “alkyloxy-” refers to the group alkyl-O-.
- Alkoxyalkyl- or “alkyloxyalkyl-” refers to the group alkyl-O-alk- wherein “alk” is an alkylene group. In “lower alkoxyalkyl-”, each alkyl and alkylene is lower alkyl and alkylene, respectively.
- Alkoxyaryl- refers to an aryl group substituted with an alkyloxy group. In “lower alkyloxyaryl-”. the alkyl group is lower alkyl.
- Alkoxycarbonyloxy- refers to alkyl-O-C(O)-O-.
- Alkyl refers to a straight or branched chain or cyclic chain hydrocarbon radical with only single carbon-carbon bonds. Representative examples include methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, cyclobutyl, pentyl, cyclopentyl, hexyl, and cyclohexyl, all of which may be optionally substituted. Alkyl groups are C 1 -C 12 .
- Alkylaryl- refers to an aryl group substituted with an alkyl group.
- “Lower alkylaryl-” refers to such groups where alkyl is lower alkyl.
- Alkylene refers to a divalent straight chain, branched chain or cyclic saturated aliphatic group. In one aspect the alkylene group contains up to and including 10 atoms. In another aspect the alkylene chain contains up to and including 6 atoms. In a further aspect the alkylene groups contains up to and including 4 atoms. The alkylene group can be either straight, branched chain or cyclic.
- Alkylthio- and alkylthio- refer to the group alkyl-S-.
- Alkylthioalkyl- refers to the group alkyl-S-alk- wherein “alk” is an alkylene group.
- alk is an alkylene group.
- lower alkylthioalkyl- each alkyl and alkylene is lower alkyl and alkylene, respectively.
- Alkylthiocarbonyloxy- refers to alkyl-S-C(O)-O-.
- Alkynyl refers to unsaturated groups which have 2 to 12 atoms and contain at least one carbon-carbon triple bond and includes straight-chain, branched-chain and cyclic groups. Alkynyl groups may be optionally substituted. Suitable alkynyl groups include ethynyl. "1-alkynyl” refers to alkynyl groups where the triple bond is between the first and second carbon atom. If the 1 -alkynyl group is attached to another group, e.g., it is a W substituent attached to the cyclic phosphonate, it is attached at the first carbon.
- Amino refers to -NR X R X wherein each R x is independently selected from hydrogen, alkyl, aryl, aralkyl and heterocycloalkyl, all except H are optionally substituted, or wherein both R x together form a cyclic ring system.
- Aminoalkyl refers to the group NR ⁇ -alk- wherein “alk” is an alkylene group and R* is selected from -H, alkyl, aryl, aralkyl, and heterocycloalkyl.
- Aminocarboxamidoalkyl refers to the group NR y 2 -C(O)-N(R y )-alk- wherein each R y is independently an alkyl group or H and “alk” is an alkylene group. “Lower aminocarboxamidoalkyl-” refers to such groups wherein “alk” is lower alkylene.
- Animal includes birds and mammals, in one embodiment a mammal, including rodents, livestock, companion animals/pets or humans of either gender.
- Alkyl refers to an alkylene group substituted with an aryl group. Suitable aralkyl groups include benzyl, picolyl, and the like, and may be optionally substituted.
- Alkoxyalkyl- refers to the group aryl-alk-O-alk- wherein “alk” is an alkylene group.
- Lower aralkyloxyalkyl- refers to such groups where the alkylene groups are lower alkylene.
- Aroyl refers to the group aryl-C(O)-.
- Aryl refers to aromatic groups which have 5-14 ring atoms and at least one ring having a conjugated pi electron system and includes carbocyclic aryl, heterocyclic aryl, bicylic aryl (e.g., naphthyl) and biaryl groups (e.g., biphenyl). all of which may be optionally substituted.
- Arylamino refers to the group aryl-NH-
- Alkyl amino refers to the group -N-alk-aryl wherein “alk” is alkylene.
- Arylene refers to divalent aromatic ring systems which have 5-14 atoms and at least one ring having a conjugated pi electron system and includes carbocyclic arylene, heterocyclic arylene and biarylene groups, all of which may be optionally substituted.
- Arylaminoalkyl- refers to the group aryl-N(R w )-alk- wherein “alk” is an alkylene group and R w is -H, alkyl, aryl, aralkyl, or heterocycloalkyl.
- R w is -H, alkyl, aryl, aralkyl, or heterocycloalkyl.
- the alkylene group is lower alkylene.
- Aryloxy refers to aryl-O-.
- Aryloxyalkyl- refers to an alkyl group substituted with an aryloxy group.
- Aryloxycarbonyl refers to the group aryl-O-C(O)-O-.
- Aryloxycarbonyloxy- refers to aryl-0-C(0)-O-.
- Atherosclerosis refers to a condition characterized by irregularly distributed lipid deposits in the intima of large and medium-sized arteries wherein such deposits provoke fibrosis and calcification.
- Biaryl represents aryl groups which have 5-14 atoms containing more than one aromatic ring including both fused ring systems and aryl groups substituted with other aryl groups. Such groups may be optionally substituted. Suitable biaryl groups include naphthyl and biphenyl.
- Binding means the specific association of the compound of interest to the target of interest, e.g., a receptor.
- C 2 -6-perfluoiOalkyP' refers to a 2 to 6 carbon alkyl group where all of the carbon atoms are exhaustively substituted with fluorine.
- Non limiting examples include trifluoromethyl, pentafluoroethyl, heptafluoropropyl, pentafluorocyclopropyl, and the like.
- C4_ 8 -cycloalkenyl refers to a non-aromatic, carbocyclic group having 4 to 8 carbon atoms and containing at least one double bond.
- Cs-s-cycloalkyloxy refers to -O-C 3 . 8 -cycloalkyl where Cs.g-cycloalkyl is an aliphatic carbocyclic group having 3 to 8 carbon atoms.
- Cs-s-cycloalkylthio refers to -S-Cs-g-cycloalkyl where Cs-g-cycloalkyl is a 3 to 8 aliphatic carbocyclic group having 3 to 8 carbon atoms
- Carboxylamido or “carboxamido” refer to NR W 2 -C(O)-, wherein each R w include -H, alkyl, aryl, aralkyl, and heterocycloalkyl.
- Carboxamidoalkylaryl refers to NR w 2 -C(O)-alk-aryl-, where R w includes H, alkyl, aryl, aralkyl, and heterocycloalkyl.
- Carboxamidoaryl refers to NR w -C(O)-aryl- wherein “alk” is alkylene and R w include H, alkyl, aryl, aralkyl, and heterocycloalkyl.
- Carbocyclic aryl groups are groups which have 6-14 ring atoms wherein the ring atoms on the aromatic ring are carbon atoms, and include monocyclic carbocyclic aryl groups and polycyclic or fused compounds such as optionally substituted naphthyl groups.
- Carboxy esters refers to -C(O)OR 7 where R z is alkyl, aryl, aralkyl, cyclic alkyl, or heterocycloalkyl, each optionally substituted.
- Carboxyl refers to -C(O)OH.
- Cyclic alkyl or “cycloalkyl” refers to alkyl groups that are cyclic of 3 to 10 carbon atoms, and, in one aspect, are 3 to 6 carbon atoms.
- the cycloalkyl groups include fused cyclic, bridged cyclic and spirocyclic groups.
- cyclic alkyl groups include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, decalin, bicycle[3.1.1]heptane, bycyclo[2.2.1]heptane, bycyclo[2.2.2]octane, bicycle[3.2.2]nonane, spiro[2.5]octane, spiro[3.5]nonane, adamantyl and the like. Such groups may be substituted.
- Cycloalkyloxy refers to the group cycloalkyl-O-.
- Cycloalkylalkoxy refers to the group cycloalkyl-alkyl-O-.
- Co-crystal as used herein means a crystalline material comprised of two or more unique solids at room temperature that are H-bonded.
- Diabetes refers to a heterogeneous group of disorders that share impaired glucose intolerance, hyperglycemia, and/or insulin resistance in common.
- Type I diabetes is characterized by pancreatic endocrine insufficiency or absence; and type II is characterized by insulin resistance. Diabetes refers to disorders in which carbohydrate utilization is reduced; and may be characterized by hyperglycemia, glycosuria, ketoacidosis, neuropathy or nephropathy, increased hepatic glucose production, insulin resistance in various tissues, insufficient insulin secretion and enhanced or poorly controlled glucagon secretion from the pancreas.
- Several pathogenic processes are involved in the development of diabetes.
- Symptoms of marked hyperglycemia include polyuria, polydipsia, weight loss, sometimes with polyphagia, and blurred vision.
- the vast majority of cases of diabetes fall into two broad etiopathogenetic categories.
- type 1 diabetes the cause is an absolute deficiency of insulin secretion.
- Individuals at increased risk of developing this type of diabetes can often be identified by serological evidence of an autoimmune pathologic process occurring in the pancreatic islets and by genetic markers.
- type 2 diabetes the cause is a combination of resistance to insulin action and an inadequate compensatory insulin secretory response.
- a degree of hyperglycemia sufficient to cause pathologic and functional changes in various target tissues, but without clinical symptoms, may be present for a long period of time before diabetes is detected.
- this asymptomatic period it is possible to demonstrate an abnormality in carbohydrate metabolism by measurement of plasma glucose in the fasting state or after a challenge with an oral glucose load.
- Criteria for the diagnosis of diabetes include:
- Casual is defined as any time of day without regard to time since last meal.
- the classic symptoms of diabetes include polyuria, polydipsia, and unexplained weight loss; or
- Fasting Plasma Glucose equal to or greater than 126 mg/dl (7.0 mmol/1). Fasting is defined as no caloric intake for at least 8 h; or
- OGTT 2-h post-meal or post oral glucose tolerance test
- Energy expenditure means basal or resting metabolic rate as defined by Schoeller et al., J Appl Physiol. ;53(4):955-9 (1982). Increases in the resting metabolic rate can be also be measured using increases in O 2 consumption and/or CO 2 efflux and/or increases in organ or body temperature.
- Enhanced oral bioavailability refers to an increase of at least 50% of the absorption of the dose of the parent drug, unless otherwise specified. In an additional aspect the increase in oral bioavailability of the prodrug (compared to the parent drug) is at least 100% (at least a doubling of the absorption). Measurement of oral bioavailability usually refers to measurements of the prodrug, drug, or drug metabolite in blood, plasma, tissues, or urine following oral administration compared to measurements following systemic administration of the compound administered orally.
- Haloalkyl refers to an alkyl group substituted with one halo (halogen group).
- Halogen or "halo” refers to -F, -Cl, -Br and -I.
- Heteroalicyclic refers to an alicyclic group or compound having 1 to 4 heteroatoms selected from nitrogen, sulfur, phosphorus and oxygen.
- Heteroarylalkyl refers to an alkylene group substituted with a heteroaryl group.
- Heteroarylene refers to a divalent, aromatic, heterocyclic ring containing 5-14 ring atoms wherein 1 to 4 heteroatoms in the aromatic ring are ring atoms and the remainder of the ring atoms being carbon atoms.
- Heteroarylene refers to a divalent heterocyclic aryl or heteroaryl group.
- Heterocyclic or “heterocyclyl” refer to cyclic groups of 3 to 10 atoms or cyclic groups of 3 to 6 atoms. These groups contain at least one heteroatom, and in some aspects contain 1 to 3 heteroatoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen. Heterocyclic groups may be attached through a nitrogen or carbon atom in the ring. Heterocyclic and heterocyclyl cyclic groups include, e.g., heterocyclic alkyl or heterocycloalkyl groups. The heterocyclic alkyl groups include unsaturated cyclic, fused cyclic and spirocyclic groups. Suitable heterocyclic groups include pyrrolidinyl, morpholino, morpholinoethyl, and pyridyl.
- Heterocyclic aryl or “heteroaryl groups” are groups which have 5-14 ring atoms wherein 1 to 4 heteroatoms are ring atoms in the aromatic ring and the remainder of the ring atoms being carbon atoms. Suitable heteroatoms include oxygen, sulfur, nitrogen, and selenium. Suitable heteroaryl groups include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolyl, pyridyl-N-oxide, pyrimidyl, pyrazinyl, imidazolyl, benzimidazolyl, benzofuranyl, benzothiophenyl, and the like, all optionally substituted.
- Hydroalkyl refers to an alkyl group substituted with one -OH.
- “Hypercholesterolemia” refers to presence of an abnormally large amount of cholesterol in the cells and plasma of the circulating blood.
- Hyperinsulinemia refers to a patient with a fasting serum insulin concentration of at least 12 ⁇ U/mL.
- Hydrolipemia refers to the presence of an abnormally large amount of lipids in the circulating blood.
- Insulin resistance is defined clinically as the impaired ability of a known quantity of exogenous or endogenous insulin to increase whole body glucose uptake and utilization.
- IGT Internet glucose tolerance
- IGT refers to a condition known to precede the development of overt Type 2 diabetes. It is characterized by abnormal blood glucose excursions following a meal. The current criteria for the diagnosis of IGT are based on 2-h plasma glucose levels post a 75g oral glucose test (144-199 mg/dL). Although variable from population to population studied, IGT progresses to full-blown NIDDM at a rate of 1.5 to 7.3% per year, with a mean of 3-4% per year. Individuals with IGT are believed to have a 6 to 10-fold increased risk in developing Type 2 diabetes. IGT is an independent risk factor for the development of cardiovascular disease.
- “Increased or enhanced liver specificity” refers to an increase in the liver specificity ratio in animals treated with a compound of the present invention and a control compound.
- One aspect of this invention provides organic radicals or compounds as containing up to and including 6 carbon atoms.
- Yet another aspect of the invention provides organic radicals or compounds that contain one to four carbon atoms. Such groups may be straight chain, branched, or cyclic.
- the ratio can be determined by measuring tissue levels at a specific time or may represent an AUC based on values measured at three or more time points.
- Methodabolic disease includes diseases and conditions such as obesity, diabetes and lipid disorders such as hypercholesterolemia, hyperlipidemia, hypertriglyceridemia as well as disorders that are associated with abnormal levels of lipoproteins, lipids, carbohydrates and insulin such as metabolic syndrome X, diabetes, impaired glucose tolerance, atherosclerosis, coronary artery disease, cardiovascular disease, polycystic ovary syndrome (PCOS).
- diseases and conditions such as obesity, diabetes and lipid disorders such as hypercholesterolemia, hyperlipidemia, hypertriglyceridemia as well as disorders that are associated with abnormal levels of lipoproteins, lipids, carbohydrates and insulin such as metabolic syndrome X, diabetes, impaired glucose tolerance, atherosclerosis, coronary artery disease, cardiovascular disease, polycystic ovary syndrome (PCOS).
- PCOS polycystic ovary syndrome
- Metal Syndrome or “Metabolic Syndrome X” refers to a condition identified by the presence of three or more of these components:
- Obsity refers to the condition of being obese. Being obese is defined as a BMI of 30.0 or greater; and extreme obesity is defined at a BMI of 40 or greater.
- “Overweight” is defined as a body mass index of 25.0 to 29.9.
- Perhalo refers to groups wherein every C-H bond has been replaced with a C-halo bond on an aliphatic or aryl group.
- Non-linking examples of perhaloalkyl groups include -CF 3 and -CFCl 2 .
- “Pharmaceutically acceptable salt” includes salts of compounds of the invention derived from the combination of a compound of this invention and an organic or inorganic acid or base.
- Suitable acids include acetic acid, adipic acid, benzcnesulfonic acid, (+) ⁇ 7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-l-methanesulfonic acid, citric acid, 1,2-ethanedisulfonic acid, dodecyl sulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glucuronic acid, hippuric acid, hydrochloride hemiethanolic acid, HBr, HCl, HI, 2-hydroxyethanesulfonic acid, lactic acid, lactobionic acid, maleic acid, methanesulfonic acid, methylbromide acid, methyl sulfuric acid, 2-naphthalenesulfonic acid, nitric acid, oleic acid,
- Preventing includes a slowing of the progress or development of a disease before onset or precluding onset of a disease.
- Prodrug refers to any compound that when administered to a biological system generates a biologically active compound as a result of spontaneous chemical reaction(s), enzyme catalyzed chemical reaction(s), and/or metabolic chemical reaction(s), or a combination of each.
- Standard prodrugs are formed using groups attached to functionality, e.g., HO-, HS-, HOOC-, .NHR, associated with the drug, that cleave in vivo.
- Standard prodrugs include but are not limited to carboxylate esters where the group is alkyl, aryl, aralkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl as well as esters of hydroxyl, thiol and amines where the group attached is an acyl group, an alkoxycarbonyl, aminocarbonyl, phosphate or sulfate.
- the groups illustrated are exemplary, not exhaustive, and one skilled in the art could prepare other known varieties of prodrugs. Such prodrugs of the compounds of the invention, fall within this scope. Prodrugs must undergo some form of a chemical transformation to produce the compound that is biologically active or is a precursor of the biologically active compound.
- the prodrug is biologically active, usually less than the drug itself, and serves to improve drug efficacy or safety through improved oral bioavailability, and/or pharmacodynamic half-life, etc.
- Prodrug forms of compounds may be utilized, for example, to improve bioavailability, improve subject acceptability such as by masking or reducing unpleasant characteristics such as bitter taste or gastrointestinal irritability, alter solubility such as for intravenous use, provide for prolonged or sustained release or delivery, improve ease of formulation, or provide site-specific delivery of the compound.
- Prodrugs are described in The Organic Chemistry of Drug Design and Drug Action, by Richard B. Silverman, Academic Press, San Diego, 1992.
- Substituted or “optionally substituted” includes groups substituted by one to six substituents, independently selected from lower alkyl, lower aryl, lower aralkyl, lower cyclic alkyl, lower heterocycloalkyl, hydroxy, lower alkoxy, lower aryloxy, perhaloalkoxy, aralkoxy, lower heteroaryl, lower heteroaryloxy, lower heteroarylalkyl, lower heteroaralkoxy, azido, amino, halo, lower alkylthio, oxo, lower acylalkyl, lower carboxy esters, carboxyl, -carboxamido, nitro, lower acyloxy, lower aminoalkyl, lower alkylaminoaryl, lower alkylaryl, lower alkylaminoalkyl, lower alkoxyaryl, lower arylamino, lower aralkylamino, sulfonyl, lower -carboxamidoalkylaryl, lower -carboxamido
- Substituted aryl and “substituted heteroaryl” refers to aryl and heteroaryl groups substituted with 1-3 substituents. These substituents are selected from the group consisting of lower alkyl, lower alkoxy, lower perhaloalkyl, halo, hydroxy, and amino.
- “Sulphonate” or “sulfonate” refers to -SO 2 OR W , where R w is -H, alkyl, aryl, aralkyl, or heterocycloalkyl.
- “Sulphonyl” or “sulfonyl” refers to -SO 2 R W , where R w is alkyl, aryl, aralkyl, or heterocyclo alkyl .
- “Therapeutically effective amount” means an amount of a compound or a combination of compounds that ameliorates, attenuates or eliminates one or more of the symptoms of a particular disease or condition or prevents, modifies, or delays the onset of one or more of the symptoms of a particular disease or condition.
- Treating" or “treatment” of a disease includes a slowing of the progress or development of a disease after onset or actually reversing some or all of the disease affects. Treatment also includes palliative treatment.
- Type 1 diabetes (formerly known as “childhood,” “juvenile,” “insulin-dependent” diabetes) is a form of diabetes characterized by an absolute deficiency of insulin secretion. Individuals at increased risk of developing this type of diabetes can often be identified by serological evidence of an autoimmune pathologic process occurring in the pancreatic islets and by genetic markers. Type 1 diabetes may be caused by immune mediated beta-cell destruction, usually leading to absolute insulin deficiency or may be idiopathic, having no known etiologies.
- Type 2 diabetes refers to a heterogeneous disorder characterized by impaired insulin secretion by the pancreas and insulin resistance in tissues such as the liver, muscle and adipose tissue.
- the manifestations of the disease include one or more of the following: impaired glucose tolerance, fasting hyperglycemia, glycosuria, decreased levels of insulin, increased levels of glucagon, increased hepatic glucose output, reduced hepatic glucose uptake and glycogen storage, reduced whole body glucose uptake and utilization, dyslipidemia, fatty liver, ketoacidosis, microvascular diseases such as retinopathy, nephropathy and neuropathy, and macrovascular diseases such as coronary heart disease.
- Phosphonate, phosphonic acid monoester and phosphinate prodrug refers to compounds that break down chemically or enzymatically to a phosphonic acid or phosphinc acid group in vivo.
- the term includes, but is not limited to, the following groups and combinations of these groups:
- acyloxyalkyl esters are possible in which a cyclic alkyl ring is formed. These esters have been shown to generate phosphorus-containing nucleotides inside cells through a postulated sequence of reactions beginning with deesterifi cation and followed by a series of elimination reactions (e.g., Freed et al., Biochem. Pharm., 38: 3193-3198 (1989)).
- alkyloxycarbonyloxymethyl esters as shown in formula A, where R a is alkoxy, aryloxy, alkylthio, arylthio, alkylamino, or arylamino; each R c is independently -H, alkyl, aryl, alkylaryl, or heterocycloalkyl have been studied in the area of ⁇ -lactam antibiotics (Nishimura et al., J. Antibiotics, 40(1): 81-90 (1987); for a review see Ferres, H., Drugs of Today, 19: 499 (1983)). More recently Cathy, M. S., et al.
- R a and R c are independently H, alkyl, aryl, alkylaryl, and alicyclic; (see WO 90/08155; WO 90/10636) and R b , for e.g., is selected from -OH, -CH 3 , -H, -0-CH 3 or monoester prodrug moiety.
- acyloxyalkyl esters are possible in which a cyclic alkyl ring is formed such as shown in formula B. These esters have been shown to generate phosphorus-containing nucleotides inside cells through a postulated sequence of reactions beginning with deesterif ⁇ cation and followed by a series of elimination reactions (e.g., Freed et al., Biochem. Pharm., 38: 3193-3198 (1989)).
- R d is -H, alkyl, aryl, alkylaryl, alkoxy, aryloxy, alkylthio, arylthio, alkylamino, arylamino, or cycloalkyl.
- Aryl esters have also been used as phosphonate prodrugs (e.g., DeLambert et al., J. Med. Chem. 37(7): 498-511 (1994); Serafmowska et al., J. Med. Chem. 38(8): 1372-9 (1995). Phenyl as well as mono and poly-substituted phenyl proesters have generated the parent phosphonic acid in studies conducted in animals and in man (Formula C). Another approach has been described where R e is a carboxylic ester ortho to the phosphate (Khamnei et al, J. Med. Chem. 39: 4109-15 (1996)).
- R e is -H, alkyl, aryl, alkylaryl, alkoxy, acyloxy, halogen, amino, alkoxycarbonyl, hydroxy, cyano, or heterocycloalkyl and R b is selected, for e.g., from -OH, - CH 3 , -H, -0-CH 3 or monoester prodrug moiety.
- Benzyl esters have also been reported to generate the parent phosphonic acid. In some cases, using substituents at the para-position can accelerate the hydrolysis.
- R and R g are independently -H, alkyl, aryl, alkylaryl, alkoxy, acyloxy, hydroxy, cyano, nitro, pcrhaloalkyl, halo, or alkyloxycarbonyl;
- R b is selected, for e.g., from -OH, -CH 3 , -H, -0-CH 3 or monoester prodrug moiety, as described therein.
- R h and R 1 are independently -H, alkyl, aryl, alkylaryl, halogen, or cyclic alkyl.
- Thio-containing phosphonate proestcrs may also be useful in the delivery of drugs to hepatocytes. These proesters contain a protected thioethyl moiety as shown in formula E.
- One or more of the oxygens of the phosphonate can be esterified. Since the mechanism that results in de-esterification requires the generation of a free thiolate, a variety of thiol protecting groups are possible. For example, the disulfide is reduced by a reductase-mediated process (Puech et al., Antiviral Res. 22: 155-174 (1993)).
- Thioesters will also generate free thiolates after esterase-mediated hydrolysis Benzaria, et al., J. Med. Chem., 39(25): 4958-65 (1996)). Cyclic analogs are also possible and were shown to liberate phosphonate in isolated rat hepatocytes. The cyclic disulfide shown below has not been previously described and is novel.
- R J is alkylcarbonyl, alkoxycarbonyl, arylcarbonyl, aryloxycarbonyl, or alkylthio and R b is selected, for e.g., from -OH, -CH 3 , -H, -0-CH 3 or monoester prodrug moiety.
- prodrugs include proester classes exemplified by Biller and Magnin (U.S. 5,157,027); Serafmowska et al., J. Med. Chem,. 38(8): 1372-9 (1995); Starrett et al., J. Med. Chem, 37: 1857 (1994); Martin et al. J. Pharm. Sci. 76: 180 (1987); Alexander et al., Collect. Czech. Chem. Commun, 59: 1853 (1994); and EP 0 632 048 Al .
- R m is -H, alkyl, cycloalkyl, or heterocycloalkyl
- R b is selected, for e.g., from -OH, -CH 3 , -H, -O-CH 3 or monoester prodrug moiety
- R k is -H, alkyl, aryl, alkylaryl, cyano, alkoxy, acyloxy, halogen, amino, heterocycloalkyl, or alkoxycarbonyl.
- the prodrugs of Formula E6 are an example of "optionally substituted heterocycloalkyl where the cyclic moiety contains a carbonate or thiocarbonate.”
- Propyl phosphonate proesters can also be used to deliver drugs into hepatocytes. These proesters may contain a hydroxyl and hydroxyl group derivatives at the 3 -position of the propyl group as shown in formula F2.
- the R n and R p groups can form a cyclic ring system as shown in formula F2.
- One or more of the oxygens of the phosphonate can be esterified.
- R n is alkyl, aryl, or heteroaryl
- R p is alkylcarbonyloxy, or alkyloxycarbonyloxy
- R is selected, for e.g., from -OH, -CH 3 , -H, -0-CH 3 or monoester prodrug moiety ;
- R q is alkyl, aryl, heteroaryl, alkoxy, alkylamino, alkylthio, halogen, hydrogen, hydroxy, acyloxy, or amino.
- Cyclic phosphoramidates have also been studied as phosphonate prodrugs because of their speculated higher stability compared to non-cyclic phosphoramidates (e.g., Starrett et al., J. Med. Chem., 37: 1857 (1994)).
- prodrugs are possible based on literature reports such as substituted ethyls for example, bis(trichloroethyl)esters as disclosed by McGuigan, et al., Bioorg Med. Chem. Lett., 3:1207-1210 (1993), and the phenyl and benzyl combined nucleotide esters reported by Meier, C. et al., Bioorg. Med. Chem. Lett. 7:99-104 (1997).
- V and W defined herein
- cyclic phosphonate ester of 1,3-propane diol refers to the following:
- the structure shown above (left) has an additional 3 carbon atoms that forms a five member cyclic group. Such cyclic groups must possess the listed substitution to be oxidized.
- the structure above has an acyloxy substituent that is three carbon atoms from a Y. and an optional substituent, -CH 3 , on the new 6-membered ring.
- cyclic phosphon(amid)ate refers to:
- cis stereochemistry refers to the spatial relationship of the V group and the carbon attached to the phosphorus atom on the six-membered ring.
- the formula below shows a cis stereochemistry.
- trans stereochemistry for the same moiety refers to the spatial relationship of the V group and the carbon, attached to the phosphorus atom, on the six-membered ring.
- the formula below shows a trans-stereochemistry.
- S-configuration refers to the absolute configuration S of carbon C.
- S-isomer refers to the absolute configuration S of carbon C.
- S-prodrug refers to the absolute configuration S of carbon C.
- the formula below shows the S-stereochemistry.
- percent enantiomeric excess refers to optical purity. It is obtained by using the following formula:
- enantioenriched or “enantiomerically enriched” refers to a sample of a chiral compound that consists of more of one enantiomer than the other. The extent to which a sample is enantiomerically enriched is quantitated by the enantiomeric ratio or the enantiomeric excess.
- glucokinase plays a critical role in the regulation of blood glucose levels. It is expressed in a restricted number of cell types, most notably the pancreatic beta-cell and liver parenchymal cells. Glucokinase catalyzes the rate-limiting step in glucose uptake, metabolism (glycolysis), and glucose storage (glycogenosis) in cells. In pancreatic beta cells, glucose uptake and metabolism trigger insulin secretion. Glucokinase is often referred to as a "glucose sensor" since it matches the rate of insulin secretion by pancreatic beta cells as well as the rate of glucose metabolism by liver cells to the ambient glucose concentrations.
- X is selected from the group consisting of aryl, hcteroaryl, alkyl, cycloalkyl, arylalkyl, aryloxy, heteroaryloxy, alkyloxy, cycloalkyloxy and arylalkyloxy;
- R ⁇ is selected from the group consisting of aryl, heteroaryl, alkyi, cycloalkyl, arylalkyl, aryloxy, heteroaryloxy, alkyloxy, cycloalkyloxy, arylalkyloxy, arylthio, heteroarylthio, cycloalkylthio and aryl alkyl thio;
- D is selected from heteroarylene and arylene, each optionally substituted
- G 1 , G 2 and G 3 are CR 4 or N;
- R 4 is H, halogen or alkyl
- R 50 is -R 6J -R 62 , and R 62 is selected from -P(O)( or -P(O)(YR 51 )Y'R 51 ;
- R 6 is selected from null, arylene, heteroarylene, arylene-alkylene, alkylene-arylene. heteroarylene-alkylene, alkylene-heteroarylene, alkylene, alkenylene, alkynylene, alkylene- Q-alkylene, -CONR 52 -alkylene, -COO-alkylene, -SO 2 NR 52 -alkylene, arylene-Q-alkylene, alkylene-Q-arylene, heteroarylene-Q-alkylene, alkylene-Q-heteroarylene, all optionally substituted;
- R 50 is not -(CH 2 )n'-Z'-(CH 2 )m'- PO(OR 63 )(OR 64 ), or -(CCH 2 )n'-Z'-(CH 2 )m'-PO(OR 63 )R 65 , or -(CH 2 )n'-Z'-(CH 2 )m'— O- PO(OR 63 )R 65 , or -(CH 2 K -Z'-(CH 2 )m'— 0-PO(R 65 )R 66 , or -(CH 2 )n'-Z'-(CH 2 )m'-PO-
- R 63 and R 64 are the same or different and are independently selected from the group consisting of hydrogen and alkyl, or R 63 and R 64 can be cyclized into a ring;
- R 65 and R 66 are the same or different and are independently selected from the group consisting of alkyl, aryl, arylalkyl, heteroaryl,and heteroarylakyl; or R 65 and R 66 can be cyclized into a ring, or R 63 and R 65 can be cyclized into a ring;
- Z' is selected from the group consisting of a bond, alkylene, alkenylene, O, S, or SO 2 ; m' is O, 1 or 2, provided that when Z is O, S or SO 2 , n' is 1 or 2; n' is 0,1, or 2;
- Y, Y 1 and Y 2 are each independently selected from -O- or -NR 60 -; wherein, when Y 2 is -O- or when Y and Y 1 are both -O-, R 51 attached to -O- is independently selected from from the group consisting of -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted
- R 51 attached to -NR 60 - is independently selected from the group consisting of -H, -[C(R 52 ) 2 ] r
- V, W, and W are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl, and
- Z is -CHR 52 OH, -CHR 52 OC(O)R 53 ,
- W and W are as defined above and together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon; or
- W and Z are as defined above and together V and W are connected via an additional
- V and W are as defined above and together Z and W are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or
- V and Z are as defined above and together W and W are connected via an additional 2-5 atoms to form a cyclic group, wherein 0-2 atoms are heteroatoms and the remaining atoms are carbon, where V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
- R 52 is R 53 or -H
- R 53 is alkyl, aryl, heterocycloalkyl or aralkyl
- R 54 is independently selected from -H or alkyl, or together R 54 and R 54 form a cycloalkylene group;
- R 6 is -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, lower acyl, Ci -6 - perfluoroalkyl or NH(CR 55 R 55 )fCH 3 ; r is an integer 2 or 3; f is an integer 0, 1 or 2; wherein, V, Z, W, W are not all -H, and when Z is -R 52 , then at least one of V, W, and W is not -H, alkyl, aralkyl, or heterocycloalkyl; and pharmaceutically acceptable salts, co-crystals and prodrugs thereof.
- X is selected from the group consisting of alkyloxy, cycloalkyloxy, alkyl and cycloalkyl;
- R 2 is -E'-E ⁇ E 3 , wherein,
- E 1 is a bond, O or S
- E 2 is a bond or alkylene; wherein, when both E 1 and E 2 are a bond, together they form a single bond;
- E 3 is optionally substituted -Ci- 4 -alkyl, optionally substituted -C 3- g-cycloalkyl or aryl, optionally substituted with one or two groups independently selected from the group consisting of aryl, heteroaryl, halogen, -Ci -4 -alkyl, -S(O) 2 R 5 or -OR 5 or R 2 selected from the group consisting of -Ci_ 4 -alkyloxy, -C ⁇ -cycloalkyloxy, benzyloxy, 2-(2-thienyl)ethyloxy, 2- (3-thienyl)ethyloxy, and phenyloxy, each optionally substituted with one or two groups independently selected from the group consisting of halogen, -C ⁇ -alkyl, -S(O) 2 C 1-4 - alkyl -S(O) 2 C 3- 6-cycloalkyl, or -OC M -alkyl;
- R 5 is alkyl or cycloalkyl
- D is heteroarylene, said heteroarylene comprising a nitrogen ring atom adjacent to a carbon ring atom, wherein said carbon ring atom is connected to the amide nitrogen atom adjacent to D, and wherein said heteroarylene has an additional 0 to 3 heteroatoms independently selected from O, S or N;
- G 1 is CH
- G 2 is CH or N
- G 3 is CH
- R 50 is -R 61 -R 62
- R 62 is selected from -P(O)( Y 2 R 51 )R ⁇ or -P(O)(YR 51 )Y 1 R 51 .
- One embodiment includes compounds of fo ⁇ nula I wherein D is a heteroarylene substituted with one or two groups independently selected from halogen and optionally substituted Ci -4 -alkyl.
- One embodiment includes compounds of formula I wherein, D is heteroarylene having a nitrogen as a ring atom, said nitrogen ring atom connected to a ring carbon atom, wherein said ring carbon atom is connected to the amide nitrogen atom that is adjacent to D. and wherein said heteroarylene has an additional 0 to 3 heteroatoms independently selected
- X is isopropyloxy or benzyloxy
- R 2 is selected from the group consisting of n-propyloxy, isopropyloxy, 2- methylpropyloxy, cylclopentylmethyloxy, benzyloxy, 2-(2-thienyl)ethyloxy, 2-(3- thienyl)ethyloxy, 2-fluorophenylmethyloxy, 4-methylsulfonylphenyloxy, A- ethylsulfonylphenyloxy and 4-isopropylsulfonylphenyloxy;
- D is pyridine-diyl or G 1 is CH; G 2 is CH; G J is CH; and
- R 50 is -R 61 -R 62
- R 62 is selected from -P(0)( Y 2 R 51 )R ] , or -P(O)(YR 5! )Y 1 R 51 .
- One embodiment includes compounds of formula I wherein, D is a heteroarylene selected from the group consisting of pyridine-diyl, thiazole-diyl, thiadiazole-diyl, pyrazol- diyl, pyrazine-diyl, pyridazine-diyl and pyrimidine-diyl, each optionally substituted with one or two groups independently selected from halogen and optionally substituted Ci -4 -alkyl; wherein, when said heteroarylene is pyridine-diyl, pyrazole-diyl, pyridaze-diyl or pyrimidine- diyl, the ring atom at position 5 of said heteroarylene is connected to R 50 and when said heteroarylene is thiazole-diyl or thiadiazole-diyl, the ring atom at position 4 of said heteroarylene is connected to R .
- D is a heteroarylene selected from the group consisting
- Another aspect of the present invention provides for compounds of general Formula II
- X is selected from the group consisting of aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, aryloxy, heteroaryloxy, alkyloxy, cycloalkyloxy and arylalkyloxy, and
- G 2 is CR 4 or N, or together G and X are connected to form a cyclic group containing 5-7 atoms, wherein 0-2 ring atoms of said cyclic group are heteroatoms and the remaining ring atoms of said cyclic group are carbon atoms optionally substituted with alkyl, aryl, cycloalkyl or heteroaryl;
- R is selected from the group consisting of arylene, heterarylene, alkylene, cycloalkylene, arylalkylene, alkylarylene, arylene-O-, heteroarylene-O-, alkylene-O-, cycloalkylene-O-, arylalkylene-O-, alkylarylene-O-, arylene-S-, arylene-SC ⁇ .
- G 1 is CR 4 or N
- G 3 is CR 4 or N
- R 4 is H, halogen or optionally substituted alkyl
- D is selected from a group consisting of heteroaryl and aryl
- R 50 is -P(O)( Y 2 R 51 ) R 1 or -P(O)(YR 51 )Y 1 R 51 ;
- Y, Y 1 and Y 2 are each independently selected from -O- or -NR 60 -; wherein, when Y 2 is -O- or when Y and Y 1 are both -0-, R 51 attached to -O- is independently selected from -H, , optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted -CHi-heterocycloakyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, -C(R 52 ) 2 OC(O)NR 52 2 , -NR 52 -C(O)-R 53 , -C(R 52 ) 2 -OC(O)R 53 , -C(R 52 ) 2 -O-C(O)OR 53 , -C(R 52 ) 2 OC(O)SR 53 , -alkyl-S-C(O)R 53 , -alkyl-S-
- R 51 are alkyl, at least one is higher alkyl; or when Y and Y 1 are independently selected from -O- and -NR 60 -, then R 51 and R 31 together form a cyclic group comprising -alkyl-S-S-alkyl-, or R 51 and R 51 together are the group
- V, W, and W are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl, and
- Z is -CHR 52 OH, -CHR 52 OC(O)R 53 ,
- W and W are as defined above and together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein O - 1 atoms are heteroatoms and the remaining atoms are carbon; or
- W and Z are as defined above and together V and W are connected via an additional 3 carbon atoms to form an optionally substituted cyclic group containing 6 carbon atoms or carbon substituted by hydrogen and substituted with one substituent selected from hydroxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy or aryloxycarbonyloxy which is attached to one of said carbon atoms that is three atoms from a Y attached to the phosphorus; or
- V and W are as defined above and together Z and W are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or
- V and Z are as defined above and together W and W are connected via an additional 2-5 atoms to form a cyclic group, wherein 0-2 atoms are heteroatoms and the remaining atoms are carbon, where V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
- R 52 is R 53 or -H
- R 53 is alkyl, aryl, heterocycloalkyl or aralkyl
- R 54 is independently selected from -H or alkyl, or together R 54 and R 54 form a cyclo alkyl en e group;
- R is -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, lower acyl, Cj -6 - perfluoroalkyl or NH(CR 55 R 55 ) jCH 3 ;
- r is an integer 2 or 3;
- f is an integer 0, 1 or 2; wherein, V, Z, W, W are not all -H, and when Z is -R 52 , then at least one of V, W, and W is not -H, alkyl, aralkyl, or heterocycloalkyl; and pharmaceutically acceptable salts and prodrugs thereof.
- X is selected from the group consisting of aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, aryloxy, alkyloxy, cycloalkyloxy and arylalkyloxy;
- R 2 is -E ! -E 2 -E 3 -E 4 -, wherein E 4 is connected to R 50 ;
- E is a bond, O or S
- E is a bond or alkylene
- E is optionally substituted C ⁇ -alkylene, optionally substituted C 3-8 - cycloalkylalkylene, arylene or heteroarylene optionally substituted with one or two groups independently selected from aryl, heteroaryl, cycloalkyl, cycloalkenyl, halogen, CN, CF 3 , NR 5 2, -Ci-4-alkyl, -S(O) 2 R 5 or -OR 5 ; wherein, when both E 1 and E 2 are a bond, together they form a single bond;
- R 5 is optionally substituted alkyl or cycloalkyl
- E is a bond or alkylene
- G 1 is CH
- G 2 is CH
- G 3 is CH
- D is heteroaryl having a nitrogen as a ring atom, said heteroaryl comprising a nitrogen ring atom adjacent to a carbon ring atom, wherein said carbon ring atom is connected to the amide nitrogen atom adjacent to D, and wherein said heteroaryl has an additional 0 to 3 heteroatoms independently selected from O, S or N; and R 50 is -P(O)( Y 2 R 51 ) R 1 or -P(O)(YR 51 )Y 1 R 51 .
- X is selected from the group consisting of isopropyloxy, benzyloxy, 1,3-difluoroprop- 2-yloxy, cyclopentyloxy, phenyloxy, 3,5-dimethylisoxazol-2-yl, phenyl and 2-methylpropyl;
- R 2 isselected from the group consisting of phenyl ene-O-, methyl ene-phenylene-O-, phenylene-methylene-O-, furan-2-yl-5-methylene, tbiophen-2-yl-5-methylene, pyridin-diyl- O-, pyrimidin-diyl-0-, pyridazin-diyl-O- and pyrazin-diyl-0-, each optionally substituted with one or two groups independently selected from aryl, heteroaryl, halogen, CN, CF 3 , NR 5 2, -Ci-4-alkyl, -S(O) 2 R " or -OR 5 , wherein R 5 is connected to R 2 by a carbon atom.
- G 1 is CH
- G 2 is CH
- G 3 is CH
- D is selected from the group consisting of pyridinyl, thiazolyl, 1,3,4-thiadiazolyl, 1,2,4-thiadiazolyl, oxazolyl, isoxazolyl, pyrazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzothiazolyl and 5,6-dihydro-4H-cyclopentathiazolyl, each optionally substituted with one or two groups selected from halogen, CF 3 , optionally substituted or Ci_ 4 -alkyl; and,
- R 50 is -P(O)(YR 51 )Y 1 R 51 .
- compounds of the invention under the conditions of Human Enzyme Assay of Example A, at a concentration of 100 ⁇ M are able to activate 50 ⁇ g of human glucokinase by at least 150%.
- compounds of the invention are able to activate glucokinae by at least 160%, 170%, 180%, 190%, 200%, 210%, 220%, 230%, 240%, 250%, 260%, 270%, 280%, 290%, 300%, 310%, 320%, 330%, 340%, 350%, 360%, 370%, 380%, 390%, 400%, 410%, 420%, 430%, 440%, 450%, 460%, 470%, 480%, 490%, 500% or at least 600% as compared to glucokinase in the absence of said compound of the present invention.
- compounds of the invention have an EC 50 of less than or equal to 5 ⁇ M in rat hepatocyte (conditions of Example B).
- compounds of the invention have an EC 50 of less than or equal to l ⁇ M in rat hepatocyte (conditions of Example B). In one embodiment, compounds of the invention have an EC 50 of less than or equal to 50OnM in rat hepatocyte (conditions of Example B).
- R 50 is selected from the group consisting Of -PO 3 H 2 , -P(O)[-OCR 52 2 OC(O)R 53 ] 2 , -P(O)[-OCR 52 2 OC(O)OR 53 ] 2 , -P(O)[-N(H)CR 52 2 C(O)OR 53 ] 2 , -P(O)[-O-alk-SC(O)R 53 ] 2 , -P(O)[-OCR 52 2 OC(O)R 53 ][- R 1 ], -PCOJt-OCR ⁇ OC ⁇ OR ⁇ Jt-R ⁇ -P ⁇ t-Nr ⁇ CR ⁇ C ⁇ OR ⁇ Jt-R 1 ], -P(O)[- OCH 2 CH 2 SC(O)R 53 ][-R'], -P(O)(OH)(YR 51 ), -P(O)(OR 56 )(OR 56 ), -P(O)(O)(OR 56 ),
- V is optionally substituted aryl or optionally substituted heteroaryl
- R 56 is -C 1 -C] 2 alkyl, -C 2 -Ci 2 alkenyl, -C 2 -C] 2 alkynyl, -(CR 57 2 ) n aryl, -(CR 57 2 ) n cycloalkyl, or -(CR 57 2 ) n heterocycloalkyl, each optionally substituted; each R 5 is independently selected from the group consisting of hydrogen, optionally substituted -C]-C 4 alkyl, halogen, optionally substituted -0-C]-C 4 alkyl, -OCF 3 , optionally substituted -S-C]-C 4 alkyl, -NR 58 R 59 , optionally substituted -C 2 -C 4 alkenyl, and optionally substituted -C 2 -C 4 alkynyl; with the proviso that when one R 57 is attached to C through an O, S, or N atom, then the other R 57
- R 58 is selected from hydrogen and optionally substituted -Cj-C 4 alkyl
- R 59 is selected from the group consisting of hydrogen and optionally substituted -Ci-C 4 alkyl, optionally substituted -C(O)-C 1 -C 4 alkyl and -C(O)H.
- R 50 is selected from the group consisting of, -
- Y and Y 1 are each independently selected from -O- and -NR 60 -; and together R 51 and R 51 are the group
- V is substituted aryl or substituted heteroaryl.
- Z is -H
- W is -H
- W is -H
- V is 3-chlorophenyl, 4-chlorophenyl, 3-bromophenyl, 3 -fluorophenyl, pyrid-4-yl, pyrid-3-yl or 3,5-dichlorophenyl.
- the relative stereochemistry between the V-group substituent and the carbon attached to the P atom of R 50 is cis.
- the relative stereochemistry between the V-group substituent and the carbon attached to the P atom of R 50 is trans.
- said compound has R stereochemistry at the carbon where the V-group is attached.
- the compound has S stereochemistry at the carbon where the V-group is attached.
- Embodiment 1 is a compound of general Formula (I),
- X is selected from the group consisting of aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, aryloxy, heteroaryloxy, alkyloxy, cycloalkyloxy and arylalkyloxy;
- R 2 is selected from the group consisting of aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, aryloxy, heteroaryloxy, alkyloxy, cycloalkyloxy, arylalkyloxy, arylthio, heteroarylthio, cycloalkyllhio and arylalkylthio;
- D is selected from heteroarylene and arylene, each optionally substituted
- G 1 , G 2 and G 3 are CR 4 or N;
- R 4 is H, halogen or alkyl
- R 50 is -R 61 -R 62
- R 62 is selected from -P(O)( Y 2 R 51 )R ] , or -P(O)(YR 51 )Y'R 51 ;
- R 61 is selected from null, arylene, heteroarylene, arylene-alkylene, alkylene-arylene, heteroarylcne-alkylene, alkylene-heteroarylene, alkylene, alkenylene, alkynylene, alkylene- Q-alkylene, -CONR 52 -alkylene, -COO-alkylene, -SO 2 NR 52 -alkylene, arylene-Q-alkylene, alkylene-Q-arylene, heteroarylene-Q-alkylene, alkylene-Q-heteroarylene, all optionally substituted;
- Q is selected from O, S, SO, SO 2 , NR 53 ; with the proviso that when D is heteroarylene then R 50 i ⁇ s not -(CH 2 )n'-Z'-(CH 2 )m'-
- R 63 and R 64 are the same or different and are independently selected from the group consisting of hydrogen and alkyl, or R and R can be cyclized into a ring;
- R 6 ⁇ and R 66 are the same or different and are independently selected from the group consisting of alkyl, aryl, arylalkyl, heteroaryl,and heteroarylalkyl; or R 65 and R 66 can be cyclized into a ring, or R 63 and R 65 can be cyclized into a ring;
- Z' is selected from the group consisting of a bond, alkylene, alkenylene, O, S, or SO 2 ; m' is 0, 1 or 2, provided that when Z is 0, S or SO 2 , n' is 1 or 2; n' is 0,1 , or 2;
- Y, Y 1 and Y 2 are each independently selected from -O- or -NR 60 -; wherein, when Y 2 is -O- or when Y and Y 1 are both -0-, R 31 attached to -O- is independently selected from from the group consisting of -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted
- R 51 attached to -NR 60 - is independently selected from the group consisting of -H, -[C(R 52 ) 2 ] r
- V, W, and W are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl, and
- Z is -CHR 52 OH, -CHR 52 OC(O)R 53 ,
- W and W are as defined above and together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon; or
- W and Z are as defined above and together V and W are connected via an additional
- V and W are as defined above and together Z and W are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or
- V and Z are as defined above and together W and W are connected via an additional 2-5 atoms to form a cyclic group, wherein 0-2 atoms are heteroatoms and the remaining atoms are carbon, where V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
- R 52 is R 53 or -H;
- R 53 is alkyl, aryl, heterocycloalkyl or aralkyl;
- R 54 is independently selected from -H or alkyl, or together R 54 and R 54 form a cycloalkylene group;
- R 60 is -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, lower acyl, C 1-6 - perfluoroalkyl or NH(CR 55 R 55 )fCH 3 ; r is an integer 2 or 3; f is an integer 0, 1 or 2; wherein, V, Z, W 5 W are not all -H, and when Z is -R 52 , then at least one of V, W, and W is not -H, alkyl, aralkyl, or heterocycloalkyl; and pharmaceutically acceptable salts, co-crystals and prodrugs thereof.
- a further embodiment is the compound of embodiment 1, wherein X is selected from the group consisting of alkyl, cycloalkyl, alkyloxy, cycloalkyloxy and aryloxy.
- a further embodiment is the compound of embodiment 1, wherein X is selected from the group consisting of alkyloxy and cycloalkyloxy.
- a further embodiment is the compound of embodiment 1 , wherein R 2 is -E ! -E 2 -E 3 , wherein,
- E 1 is a bond, O or S
- E is a bond or alkylene; wherein, when both E 1 and E are a bond, together they form a single bond;
- E is optionally substituted -C 1-4 -alkyl, optionally substituted -C 3-8 -cycloalkyl or aryl optionally substituted with one or two groups independently selected from the group consisting of aryl, heteroaryl, halogen, -Ci -4 -alkyl, -S(O) 2 R 5 or -OR 5 ;
- R is alkyl or cycloalkyl.
- a further embodiment is the compound of embodiment 1, wherein R 2 is selected from the group -C 3-6 -cycloalkyloxy, benzyloxy, 2- (2-thienyl)ethyloxy, 2-(3-thienyl)ethyloxy, and phenyloxy, each optionally substituted with one or two groups independently selected from the group consisting of halogen, -Cj -4 - alkyl, -S(O) 2 Ci J t-alkyl, -S(O) 2 C 3 ⁇ -cycloalkyl ⁇ or -OC M -alkyl.
- a further embodiment is the compound of embodiment 1, wherein R' is selected from the group consisting of n-propyloxy, isopropyloxy, 2-methylpropyloxy, cylclopentylmethyloxy, benzyloxy. 2-(2-thienyl)ethyloxy, 2-(3-thienyl)ethyloxy, 2- fluorophenylmethyloxy, 4-methylsulfonylphenyloxy, 4-ethylsulfonylphenyloxy and 4- isopropylsulfonylphenyloxy.
- a further embodiment is the compound of embodiment 1, wherein D is heteroarylene, said heteroarylene comprising a nitrogen ring atom adjacent to a carbon ring atom, wherein said carbon ring atom is connected to the amide nitrogen atom adjacent to D, and wherein said heteroarylene has an additional 0 to 3 heteroatoms independently selected from O, S or N.
- a further embodiment is the compound of embodiment 1, wherein D is a heteroarylene, optionally substituted with one or two groups independently selected from halogen and optionally substituted wherein, when said heteroarylene is pyridine-diyl, pyrazole-diyl, pyridaze-diyl or pyramidine-diyl, the ring atom at position 5 of said heteroarylene is connected to R 50 and when said heteroarylene is thiazole-diyl or thiadiazole-diyl, the ring atom at position 4 of said heteroarylene is connected to R , and n is O or 1.
- a further embodiment is the compound of embodiment 1 , wherein G 1 , G 2 and G 3 are CR 4 and R 4 is H, halogen or alkyl.
- a further embodiment is the compound of embodiment 9, wherein R 4 is H.
- a further embodiment is the compound of embodiment 1, wherein R 62 is selected from the group consisting of:
- V is optionally substituted aryl or optionally substituted heteroaryl
- R 56 is -Ci-C 12 alkyl, -C 2 -Ci 2 alkenyl, -C 2 -Ci 2 alkynyl, -(CR 57 2 ) n aryl, -(CR 57 2 ) n cycloalkyl, or -(CR 57 2 ) ⁇ heterocycloalkyl, each optionally substituted; each R 57 is independently selected from the group consisting of hydrogen, optionally substituted -Ci-C 4 alkyl, halogen, optionally substituted -O-C 1 -C 4 alkyl, -OCF 3 , optionally substituted -S-Ci-C 4 alkyl, -NR 58 R 59 , optionally substituted -C 2 -C 4 alkenyl, and optionally substituted -C 2 -C 4 alkynyl; with the proviso that when one R 57 is attached to C through an O, S, or N atom, then the other R
- R 58 is selected from hydrogen and optionally substituted -Ci-C 4 alkyl
- R 5 is selected from the group consisting of hydrogen and optionally substituted -Ci-C 4 alkyl, optionally substituted -C(O)-Ci-C 4 alkyl and -C(O)H.
- a further embodiment is the compound of embodiment 1, wherein R 62 is selected from the group consisting of:
- V is substituted aryl or substituted heteroaryl.
- a further embodiment is the compound of embodiment 1, wherein said compound has one of the following combinations of substituents:
- X is selected from the group consisting of aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, aryloxy, heteroaryloxy, alkyloxy. cycloalkyloxy and arylalkyloxy; or
- X is selected from the group consisting of alkyl, cycloalkyl, alkyloxy, cycloalkyloxy and aryloxy; or
- X is selected from the group consisting of alkyloxy and cycloalkyloxy
- Substituent 2 is R 2 and:
- R 2 is selected from the group consisting of aryl, heteroaryl. alkyl, cycloalkyl, arylalkyl, aryloxy, heteroaryloxy, alkyloxy, cycloalkyloxy, arylalkyloxy, arylthio, heteroarylthio, cycloalkylthio and arylalkylthio; or
- R 2 is -E 1 -E 2 -E 3 , wherein,
- E 1 is a bond, O or S
- E ⁇ is a bond or alkylene; wherein, when both E 1 and E 2 are a bond, together they form a single bond;
- E is optionally substituted -Ci -4 -alkyl, optionally substituted -Cs-s-cycloalkyl or aryl optionally substituted with one or two groups independently selected from the group consisting of halogen, -C 1-4 -alkyl, -S(O) 2 R 5 and -OR 5 ;
- R 5 is alkyl or cycloalkyl
- R 2 is selected from the group consisting of -C ⁇ -alkyloxy, -Cs.g-cycloalkyloxy, benzyloxy, 2-(2-thienyl)ethyloxy, 2-(3-thienyl)ethyloxy, and phenyloxy, each optionally substituted with one or two groups independently selected from the group consisting of halogen, -C 1-4 -alkyl. -S(O) 2 Ci-4-alkyl, -S(O)2C3. 6 -cycloalkyl, or -OC 1-4 -alkyl; or
- R is selected from the group consisting of n-propyloxy, isopropyloxy, 2- methylpropyloxy, cylclopentylmelhyloxy, benzyloxy, 2-(2-thienyl)ethyloxy, 2-(3- thienyl)ethyloxy, 2-fluorophenylmethyloxy, 4-methylsulfonylphenyloxy, A- ethylsulfonylphenyloxy and 4-isopropylsulfonylphenyloxy;
- Substituent 3 is D and:
- D is selected from heteroarylene or arylene, each optionally substituted;
- D is heteroarylene, said heteroarylene comprising a nitrogen ring atom adjacent to a carbon ring atom, wherein said carbon ring atom is connected to the amide nitrogen atom adjacent to D, and wherein said heteroarylene has an additional 0 to 3 heteroatoms independently selected from O, S or N; or
- D is a heteroarylene, optionally substituted with one or two groups independently selected from halogen and optionally substituted wherein, when said heteroarylene is pyridine-diyl. pyrazole-diyl, pyridaze-diyl or pyramidine-diyl, the ring atom at position 5 of said heteroarylene is connected to R 50 and when said heteroarylene is thiazole-diyl or thiadiazole-diyl, the ring atom at position 4 of said heteroarylene is connected to R 50 , and n is O or 1;
- Substituent 4 is G 1 , G 2 and G 3 and:
- G 1 , G 2 and G 3 are CR 4 or N; and R 4 is H, halogen or alkyl; or GG 11 iiss CCRR 44 ;; GG 22 iiss CCRR 44 ;; GG 33 iiss CCRR 44 ;; aanndd RR 44 is H, halogen or alkyl; or G 1 is CH; G 2 is CH; and G 3 is CH; and
- Substituent 5 is R 50 and:
- R 50 is -R 61 -R 62
- R 62 is selected from -P(O)( Y 2 R 51 )R 1 , or -P(O)(YR 51 )Y'R 51
- R l is selected from null, arylene, heteroarylene, arylene-alkylene, alkylene-arylene, heteroarylene-alkylene, alkylene-heteroarylene, alkylene, alkenylene, alkynylene, alkylene-Q-alkylene, -CONR 52 -alkylene, -COO-alkylene, -SO 2 NR 52 -alkylene, arylene-Q-alkylene, alkylene-Q-arylene, heteroarylene-Q-alkylene, alkylene-Q- heteroarylene, all optionally substituted;
- Q is selected from O, S, SO. SO 2 , NR 53 ;
- Y, Y 1 and Y 2 are each independently selected from -O- or -NR 60 -; wherein, when Y 2 is -O- or when Y and Y 1 are both -0-, R 51 attached to -O- is independently selected from from the group consisting of -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted -CH 2 -heterocycloakyl with a cyclic moiety containing a carbonate or thiocarbonate, optionally substituted -alkylaryl, -C(R 52 ) 2 OC(O)NR 52 2 , -NR 52 -C(O)-R 53 , -C(R 52 ) 2 -OC(O)R 53 , -C(R 52 ) 2 -O -C(O)OR 53 , -C(R 52 ) 2 OC(O)SR 53 , -alkyl-S-C(O)R
- V, W, and W are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl, and
- Z is -CHR 52 OH, -CHR 52 OC(O)R 53 ,
- W and W are as defined above and together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon; or
- W * and Z are as defined above and together V and W are connected via an additional 3 carbon atoms to form an optionally substituted cyclic group containing 6 carbon atoms or carbon substituted by hydrogen and substituted with one substituent selected from hydroxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy or aryloxycarbonyloxy which is attached to one of said carbon atoms that is three atoms from a Y attached to the phosphorus; or
- V and W are as defined above and together Z and W are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or
- V and Z are as defined above and together W and W are connected via an additional 2-5 atoms to form a cyclic group, wherein 0-2 atoms are heteroatoms and the remaining atoms are carbon, where V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
- R 52 is R 53 or -H
- R 53 is alkyl. aryl, heterocycloalkyl or aralkyl
- R 54 is independently selected from -H or alkyl, or together R 54 and R 54 form a cycloalkylene group:
- R is -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, lower acyl, Ci -6 - perfluoroalkyl or NH(CR 55 R 55 ) f CH 3 ; r is an integer 2 or 3; f is an integer 0, 1 or 2; wherein, V, Z, W, W are not all -H, and when Z is -R 52 , then at least one of V, W, and W is not -H, alkyl, aralkyl, or heterocycloalkyl; or
- R 62 is selected from the group consisting of:
- V is optionally substituted aryl or optionally substituted heteroaryl
- R 56 is -Ci-Ci 2 alkyl, -C 2 -C 12 alkenyl, -C 2 -Ci 2 alkynyl, -(CR 57 2 ) n aryl. -(CR 57 2 ) n cycloalkyl, or -(CR 57 2 ) n heterocycloalkyl, each optionally substituted; each R is independently selected from the group consisting of hydrogen, optionally substituted -Cj-C 4 alkyl, halogen, optionally substituted -0-Ci-C 4 alkyl, -OCF 3 , optionally substituted -S-Ci -C 4 alkyl, -NR 58 R 59 , optionally substituted -C 2 -C 4 alkenyl, and optionally substituted -C 2 -C 4 alkynyl; with the proviso that when one R 57 is attached to C through an O, S, or N atom, then the other R 37 attached to the
- R is selected from hydrogen and optionally substituted -Ci -C 4 alkyl; and.
- R 5 is selected from the group consisting of hydrogen and optionally substituted -Ci-C 4 alkyl, optionally substituted -C(O)-Ci-C 4 alkyl and -C(O)H; or
- R 6 is selected from the group consisting of -
- a further embodiment is the compound of embodiment 14, wherein: Substituent 1 is X and:
- X is selected from the group consisting of aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, aryloxy, heteroaryloxy, alkyloxy, cycloalkyloxy and arylalkyl oxy;
- Substituent 2 is R 2 and:
- R 2 is selected from the group consisting of aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, aryloxy, heteroaryloxy, alkyloxy, cycloalkyloxy, arylalkyloxy, arylthio, heteroarylthio, cycloalkylthio and arylalkylthio;
- Substituent 3 is D and:
- D is selected from heteroarylene or arylene, each optionally substituted
- Substituent 4 is G 1 , G 2 and G 3 and:
- G 1 , G 2 and G 3 are CR 4 or N; and R 4 is H, halogen or alkyl;
- Substituent 5 is R 50 and:
- R 50 is -R 61 -R 62
- R 62 is selected from -P(O)( YV)R 1 , or -P(O)(YR ⁇ )Y 1 R 51
- R 61 is selected from null, arylene, heteroarylene, arylene-alkylene, alkylcne-arylene, heteroarylene-alkylene, alkylene-heteroarylene, alkylene, alkenylene, alkynylene, alkylene-Q-alkylene, -CONR 52 -alkylene, -COO-alkylene, -SO 2 NR 52 -alkylene, arylene-Q-alkylene, alkylene-Q-arylene, heteroarylene-Q-alkylene, alkylene-Q- heteroarylene, all optionally substituted;
- Q is selected from O, S, SO, SO 2 , NR 53 ;
- R 1 is selected from the group consisting of hydrogen, optionally substituted -
- R 5! attached to -NR 60 - is independently selected from the group consisting of -H, -[C(R 52 ) 2 ] r -COOR 53 , -C(R 54 ) 2 COOR 53 , -[C(R 52 ) 2 ] r -C(O)SR 53 .
- R 51 attached to -O- is independently selected from -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH 2 -heterocycloakyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, -C(R 52 ) 2 OC(O)NR 52 2 .
- R 51 attached to -NR 60 - is independently selected from -H, -[C(R 52 H-COOR 53 , -C(R 54 ) 2 COOR 53 , -[C(R 52 ) 2 ] r -C(O)SR 53 , and -cycloalkylene-COOR 53 , wherein if both R 3 are alkyl, at least one is higher alkyl; or when Y and Y 1 are independently selected from -O- and -NR 60 -, then R
- V, W, and W are independently selected from the group consisting of hydrogen. optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl. optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl, and
- Z is -CHR 52 OH, -CHR 52 OC(O)R 53 ,
- W and W are as defined above and together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon; or
- W and Z are as defined above and together V and W are connected via an additional 3 carbon atoms to form an optionally substituted cyclic group containing 6 carbon atoms or carbon substituted by hydrogen and substituted with one substituent selected from hydroxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy or aryloxycarbonyloxy which is attached to one of said carbon atoms that is three atoms from a Y attached to the phosphorus; or
- V and W are as defined above and together Z and W are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or
- V and Z are as defined above and together W and W are connected via an additional 2-5 atoms to form a cyclic group, wherein 0-2 atoms are heteroatoms and the remaining atoms are carbon, where V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
- R 52 is R 53 or -H
- R 53 is alkyl, aryl, heterocycloalkyl or aralkyl:
- R 54 is independently selected from -H or alkyl, or together R 34 and R 54 form a cycloalkylene group;
- R 60 is -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, lower acyl, Ci. ⁇ - perfluoroalkyl or NH(CR 55 R 55 ) t CH 3 ; r is an integer 2 or 3; f is an integer 0, 1 or 2; wherein, V, Z, W, W are not all -H, and when Z is -R 52 , then at least one of V, W, and W is not -H, alkyl, aralkyl, or heterocycloalkyl
- a further embodiment is the compound of embodiment 14, wherein: Substituent 1 is X and: X is selected from the group consisting of alkyl. cycloalkyl. alkyloxy, cycloalkyloxy and aryloxy;
- Substituent 2 is R" and:
- R 2 is -E'-E ⁇ E 3 , wherein.
- E 1 is a bond, O or S
- E 2 is a bond or alkylene; wherein, when both E 1 and E 2 are a bond, together they form a single bond;
- E 3 is optionally substituted -C M -alkyl, optionally substituted -C ⁇ -cycloalkyl or aryl optionally substituted with one or two groups independently selected from the group consisting of halogen, -C M -alkyl, -S(O) 2 R 3 Or -OR 5 ;
- R D is alkyl or cycloalkyl
- R is selected from the group consisting of -Ci- 4 -alkyloxy, -C 3 - 6 -cycloalkyloxy, benzyloxy, 2-(2-thienyl)ethyloxy, 2-(3-thienyl)ethyloxy, and phenyl oxy, each optionally substituted with one or two groups independently selected from the group consisting of halogen, -C M -alkyl, -S(O) 2 C, -4 -alkyL -S(O) 2 C 3-6 -cycloalkyl, or -OC 1-4 -alkyl;
- Substituent 3 is D and:
- D is heteroarylene, alkylene-heteroarylene, or arylene-heteroarylene, said heteroarylene comprising a nitrogen ring atom adjacent to a carbon ring atom, wherein said carbon ring atom is connected to the amide nitrogen atom adjacent to D. and wherein said heteroarylene has an additional 0 to 3 heteroatoms independently selected from O. S or N;
- Substituent 4 is G 1 , G 2 and G 3 and:
- G 1 is CR 4 ;
- G 2 is CR 4 ;
- G 3 is CR 4 ; and
- R 4 is H. halogen or alkyl;
- Substituent 5 is R 62 and:
- R 62 is selected from the group consisting of:
- V is optionally substituted aryl or optionally substituted heteroaryl;
- R 56 is -Ci-Ci 2 alkyl, -C 2 -Ci 2 alkenyl, -C 2 -Ci 2 alkynyl, -(CR 57 2 ) n aryL -(CR 57 2 ) n cycloalkyl, or -(CR 57 2 ) n heterocycloalkyl, each optionally substituted; each R 57 is independently selected from the group consisting of hydrogen, optionally substituted -Ci-C 4 alkyl, halogen, optionally substituted -0-Cj-C 4 alkyl, -OCF 3 , optionally substituted -S-Cj-C 4 alkyl, -NR 58 R 59 , optionally substituted -C 2 -C 4 alkenyl, and optionally substituted -C 2 -C 4 alkynyl; with the proviso that when one R 3 is attached to C through an O, S, or N atom, then the other R 37 attached to the
- R 58 is selected from hydrogen and optionally substituted -Cj-C 4 alkyl
- R 59 is selected from the group consisting of hydrogen and optionally substituted -C 1 -C 4 alkyl, optionally substituted -C(O)-Cj-C 4 alkyl and -C(O)H .
- a further embodiment is the compound of embodiment 14, wherein: Substituent 1 is X and:
- X is selected from the group consisting of alkyloxy and cycloalkyloxy
- Substituent 2 is R 2 and:
- R 2 is selected from the group -Cs. ⁇ -cycloalkyloxy, benzyloxy, 2-(2-thienyl)ethyloxy, 2-(3-thienyl)ethyloxy, and phenyloxy, each optionally substituted with one or two groups independently selected from the group consisting of halogen, -C 1-4 -alkyL -S(O) 2 Cj - 4 -alkyl, -S(O) 2 C 3-6 -cycloa]kyl, or -OC 1-4 -alkyl: or
- Substituent 3 is D and:
- D is a heteroarylene, optionally substituted with one or two groups independently selected from halogen and optionally substituted Cj 4 -alkyl; wherein, when said heteroarylene is pyridine-diyl, pyrazole-diyl, pyridaze-diyl or pyramidine-diyl, the ring atom at position 5 of said heteroarylene is connected to R 3 ⁇ and when said heteroarylene is thiazole-diyl or thiadiazole-diyl, the ring atom at position 4 of said heteroarylene is connected to R 3 ⁇ , and n is O or 1; Substituent 4 is G 1 , G 2 and G 3 and:
- Substituent 5 is R 62 and:
- R 62 is selected from the group consisting of -
- a further embodiment is the compound of embodiments 14, 15, 16 or 17, wherein R " is selected from the group consisting of n-propyloxy, isopropyloxy, 2- methylpropyloxy, cylclopentylmethyloxy, benzyloxy, 2-(2-thienyl)ethyloxy, 2-(3- thienyl)ethyloxy, 2-fluorophenylmethyloxy, 4-methylsulfonylphenyloxy, 4- ethylsulfonylphenyloxy and 4-isopropylsulfonylphenyloxy.
- a further embodiment is the compound according to any of embodiments 1-18, wherein R 61 is selected from null, arylene, heteroarylene, arylene- alkylene, alkylene-arylene, heteroarylene-alkylene, alkylene-heteroarylene, -CONR""- alkylene, -COO-alkylene or -SO 2 NR 32 -alkylene, and all groups are optionally substituted.
- R l is selected from null, arylene. heteroarylene, and all group are optionally substituted.
- a further embodiment is a compound of general Formula (II),
- X is selected from the group consisting of aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, aryloxy, heteroaryloxy, alkyloxy, cycloalkyloxy and arylalkyl oxy, and
- G 2 is CR 4 or N, or together G 2 and X are connected to form a cyclic group containing 5-7 atoms, wherein 0-2 atoms of said cyclic group are heteroatoms and the remaining atoms of said cyclic group are carbon atoms substituted with alkyl, aryl, cycloalkyl or heteroaryl;
- R 2 is optionally substituted and is selected from arylene, heteroarylene, alkylene, cycloalkylene, arylalkylene, alkylarylene, arylene-O-, heteroarylene-O-, alkylene-O, cycloalkylene-O-, arylalkylene-0-, alkylarylene-O-, arylene-S-, heteroarylene-S-, alkylene-S- , cycloalkylene-S-, arylalkylene-S-, or alkylarylene-S-, wherein R 2 is connected to R 50 by a C atom;
- G 1 is CR 4 or N
- R 4 is H, halogen or optionally substituted alkyl
- G 3 is CR 4 or N
- R 4 is H, halogen or optionally substituted alkyl
- D is selected from a group consisting of heteroaryl or aryl
- R 50 is -P(O)( Y 2 R 51 ) R 1 or -P(O)(YR 5! )Y 1 R 51 ;
- Y, Y 1 and Y 2 are each independently selected from -O- or -NR 60 -: wherein, when Y 2 is -O- or when Y and Y 1 are both -O-, R 51 attached to -O- is independently selected from -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted -CH 2 -heterocycloakyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, -C(R 52 ) 2 OC(O)NR 52 2 , -NR 52 -C(O)-R 53 , -C(R 52 ) 2 -OC(O)R 53 , -C(R 52 ) 2 -O -C(O)OR 53 , -C(R 52 ) 2 OC(O)SR 53 , -alkyl-S-C(O)R 53 , -al
- R 51 attached to -NR 60 - is independently selected from -H, -[C(R 52 ) 2 ] r COOR 53 , -C(R 54 ) 2 COOR 53 , -[C(R 52 ) 2 ] r -C(O)SR 53 , and -cycloalkylene-COOR 33 , wherein if both R 51 are alkyl, at least one is higher alkyl; or when Y and Y 1 are independently selected from -O- and -NR 60
- V, W, and W are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl, and
- Z is -CHR 52 OH, -CHR 52 OC(O)R 53 .
- W and W are as defined above and together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon; or
- W and Z are as defined above and together V and W are connected via an additional 3 carbon atoms to form an optionally substituted cyclic group containing 6 carbon atoms or carbon substituted by hydrogen and substituted with one substituent selected from hydroxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy or aryloxycarbonyloxy which is attached to one of said carbon atoms that is three atoms from a Y attached to the phosphorus; or
- V and W are as defined above and together Z and W are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or
- V and Z are as defined above and together W and W are connected via an additional 2-5 atoms to form a cyclic group, wherein 0-2 atoms are heteroatoms and the remaining atoms are carbon, where V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
- R 52 is R 53 or -H;
- R 53 is alkyl, aryl, heterocycloalkyl or aralkyl;
- R 54 is independently selected from -H or alkyl, or together R 54 and R 54 form a cycloalkylene group;
- R is -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, lower acyl, Ci -6 - perfluoroalkyl or NH(CR 55 R 55 ),CH 3 ; r is an integer 2 or 3; f is an integer 0, 1 or 2; wherein. V, Z, W, W are not all -H, and when Z is -R 52 , then at least one of V, W, and W is not -H, alkyl, aralkyl, or heterocycloalkyl; and pharmaceutically acceptable salts, co-crystals and prodrugs thereof.
- a further embodiment is the compound of embodiment 21, wherein X is selected from the group consisting of alkyl. cycloalkyl, alkyloxy, cycloalkyloxy and aryloxy.
- a further embodiment is the compound of embodiment 21, wherein X is selected from the group consisting of alkyloxy and cycloalkyloxy.
- a further embodiment is the compound of embodiment 21, wherein X is selected from the group consisting of aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, aryloxy, heteroaryloxy, alkyloxy, cycloalkyloxy and aryl alkyloxy.
- a further embodiment is the compound of embodiment 21, wherein R 2 is -E'-E ⁇ -E 4 -, wherein E 4 is connected to R 50 ;
- E 1 is a bond, O or S
- E is a bond or alkylene
- E 3 is optionally substituted Ci-4-alkylene, optionally substituted C 3-8 - cycloalkylalkylene, arylene or heteroarylene optionally substituted with one or two groups independently selected from aryl, heteroaryl, cycloalkyl, cycloalkenyl, halogen, CN, CF 3 , NR 5 2, -Ci-4-alkyl, -S(O) 2 R 5 or -OR 5 ; wherein, when both E 1 and E 2 are a bond, together they form a single bond;
- R 5 is optionally substituted alkyl or cycloalkyl
- E 4 is a bond or alkylene.
- a further embodiment is the compound of embodiment 21, wherein R" is selected from the group consisting of phenyl ene-0-, methylene-phenylene-O-, phenylene-methylene-O-, furan-2-yl-5-methylene, thiophen-2-yl-5-methylene, pyridin-diyl- O-, pyrimidin-diyl-O-, pyridazin-diyl-O- and pyrazin-diyl-O-, each optionally substituted with one or two groups independently selected from aryl, heteroaryl, halogen, CN, CF 3 , NR 5 2 , -Ci-4-alkyl, -S(O) 2 R 5 or -OR 5 , wherein R 50 is connected to R 2 by a carbon atom.
- a further embodiment is the compound of embodiment 21, wherein R 2 is methylene-thiophen-2,5-diyl, phenylene-O- or thiophen-2-yl-5-methylene, wherein R is connected to the phenylene or thiophenyl group.
- a further embodiment is the compound of embodiment 21, wherein R 2 is optionally substituted and is selected from arylene, heteroarylene, alkylene, cycloalkylene, arylalkylene, alkylarylene, arylene-O-, heteroaryiene-O, alkylene-O-, cycloalkylene-O-, arylalkylene-O-, alkylarylene-O-, arylene-S-, heteroarylene-S-, alkylene-S- , cycloalkylene-S-, arylalkylene-S-, or alkylarylene-S-, wherein R 5 is connected to R 2 by a carbon atom.
- a further embodiment is the compound according to embodiment 21, wherein G 1 and G 2 are CR 4 or N.
- a further embodiment is the compound of embodiment 21 , wherein G and G are CR and R is H, halogen or optionally substituted alkyl.
- a further embodiment is the compound according to embodiment 30, wherein R 4 is H.
- a further embodiment is the compound of embodiment 21, wherein G 3 is CR 4 or N.
- a further embodiment is the compound of embodiment 21, wherein G 3 is CR 4 and R 4 is H, halogen or optionally substituted alkyl.
- a further embodiment (“Embodiment 34”) is the compound of embodiment 21, wherein R 4 is H.
- a further embodiment is the compound of embodiment 21, wherein D is selected from a group consisting of heteroaryl or aryl.
- a further embodiment is the compound of embodiment 21 , wherein D is a heteroaryl having a nitrogen as a ring atom, said heteroaryl comprising a nitrogen ring atom adjacent to a carbon ring atom, wherein said carbon ring atom is connected to the amide nitrogen atom adjacent to D, and wherein said heteroaryl has an additional 0 to 3 heteroatoms independently selected from O, S or N.
- a further embodiment is the compound of embodiment 21 , wherein D is selected from the group consisting of pyridinyl, thiazolyl. 1,3.4-thiadiazolyl, 1.2,4-thiadiazolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzothiazolyl and 5,6-dihydro-4H-cyclopentathiazolyl. each optionally substituted with one or two groups selected from halogen, CF 3 . or optionally substituted C 1-4 - alkyl.
- a further embodiment is the compound of embodiment 21, wherein D is selected from the group consisting of thiazolyl, 1,3,4-thiadiazolyl. and 1, 2,4- thiadiazolyl, each optionally substituted with one or two groups selected from halogen, CF 3 , or optionally substituted Ci. 4 -alkyl.
- a further embodiment is the compound of embodiment 21 , wherein R 50 is -P(O)( Y 2 R 51 ) R 1 or -P(O)(YR 51 )Y 1 R 51 ;
- R 1 is selected from the group consisting of hydrogen, optionally substituted -Ci-C 6 - alkyl, -CF 3 , -CHF 2 , -CH 2 F, -CH 2 OH, optionally substituted -C 2 -C 6 alkenyl, optionally substituted -C 2 -C 6 alkynyl, optionally substituted -(CR 52 2 ) n cycloalkyl, optionally substituted (CR 52 2 ) n heterocycloalkyl, -(CR 52 2 ) k
- Y, Y 1 and Y 2 are each independently selected from -O- or -NR 60 -; wherein. when Y 2 is -O- or when Y and Y 1 are both -O-, R 51 attached to -0- is independently selected from -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted -CH 2 -heterocycloakyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, -C(R 52 ) 2 OC(O)NR 52 2 , -NR 52 -C(O)-R 53 , -C(R 52 ) 2 -OC(O)R 53 , -C(R 52 ) 2 -O -C(O)OR 53 , -C(R 52 ) 2 OC(O)SR 53 , -alkyl-S-C(O)R 53 , -alky
- optionally substituted heterocycloalkyl optionally substituted CH 2 -heterocycloakyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, -C(R 52 ) 2 OC(O)NR 52 2 , -NR 52 -C(O)-R 53 , -C(R 52 ) 2 -OC(O)R 53 , -C(R 52 ) 2 -O -C(O)OR 53 , -C(R 52 ) 2 OC(O)SR 53 , -alkyl-S-C(O)R 53 , -alkyl-S-S-alkylhydroxy, and -alkyl-S-S-S-alkylhydroxy, and R 31 attached to -NR 60 - is independently selected from -H, -[C(R 52 ) 2 ] r -COOR 53 , -C(R 54 ) 2 COOR 53 , and
- V, W, and W are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1 -alkynyl, and
- Z is -CHR 52 OH, -CHR 52 OC(O)R 53 ,
- W and W are as defined above and together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0 - 1 atoms are heteroatoms and the remaining atoms are carbon; or
- W and Z are as defined above and together V and W are connected via an additional 3 carbon atoms to form an optionally substituted cyclic group containing 6 carbon atoms or carbon substituted by hydrogen and substituted with one substituent selected from hydroxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy or aryloxycarbonyloxy which is attached to one of said carbon atoms that is three atoms from a Y attached to the phosphorus; or
- V and W are as defined above and together Z and W are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or
- V and Z are as defined above and together W and W are connected via an additional 2-5 atoms to form a cyclic group, wherein 0-2 atoms are heteroatoms and the remaining atoms are carbon, where V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
- R 52 is R 53 or -H
- R 53 is alkyl, aryl, heterocycloalkyl or aralkyl
- R 54 is independently selected from -H or alkyl, or together R M and R 54 form a cycloalkylene group;
- R 60 is -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, lower acyl, C 1-6 - perfluoroalkyl or NH(CR 55 R 55 ) f CH 3 ; r is an integer 2 or 3 ; f is an integer O, 1 or 2; wherein, V, Z, W, W are not all -H, and when Z is -R 32 , then at least one of V, W, and W is not -H, alkyl, aralkyl, or heterocycloalkyl.
- a further embodiment (“Embodiment 40") is the compound of embodiment 21, wherein R 50 is selected from the group consisting
- V is optionally substituted aryl or optionally substituted heteroaryl
- R 56 is -Ci-C 12 alkyl, -C 2 -C n alkenyl, -C 2 -Ci 2 alkynyl, -(CR 57 2 ) n aryl, -(CR 57 2 ) n cycloalkyl, or -(CR 57 2 ) n heterocycloalkyl, each optionally substituted; each R 57 is independently selected from the group consisting of hydrogen, optionally substituted -Ci-C 4 alkyl, halogen, optionally substituted -0-Cj-C 4 alkyl, -OCF 3 .
- R 58 is selected from hydrogen and optionally substituted -Cj-C 4 alkyl; and.
- R 59 is selected from the group consisting of hydrogen and optionally substituted -C, -C 4 alkyl, optionally substituted -C(O)-Ci-C 4 alkyl and -C(O)H.
- a further embodiment is the compound of embodiment 21, wherein R 50 is selected from the group consisting of
- a further embodiment is the compound of embodiment 21, wherein Y and Y 1 are each independently selected from -O- and -NR 60 -; and together R 51 and R 51 are the group
- V is substituted aryl or substituted heteroaryl.
- a further embodiment is the compound of embodiment 21 , wherein G is CR or N, or together G and X are connected to form a cyclic group containing 5-7 atoms, wherein 0-2 atoms of said cyclic group are heteroatoms and the remaining atoms of said cyclic group are carbon atoms substituted with alkyl, aryl, cycloalkyl or heteroaryl.
- a further embodiment is the compound of embodiment 43, wherein G 2 is CR 4 .
- a further embodiment is the compound of embodiment 44, wherein R 4 is H.
- a further embodiment is the compound of embodiment 43, wherein together G 2 and X are connected to form a cyclic group containing 5-7 atoms, wherein 0-2 atoms of said cyclic group are heteroatoms and the remaining atoms of said cyclic group are carbon atoms substituted with alkyl, aryl, cycloalkyl or heteroaryl.
- a further embodiment (“Embodiment 47”) is the compound of embodiment 43, wherein G is N.
- a further embodiment is the compound of embodiment 21, wherein:
- X is selected from the group consisting of alkyloxy and cycloalkyloxy
- R 2 is selected from the group consisting of phenylene-O-, methylene-phenylene-O-, phenylene-methylene-O-, furan-2-yl-5-methylene, thiophen-2-yl-5-methylene, pyridin-diyl- O-, pyrimidin-diyl-O-, pyridazin-diyl-O- and pyrazin-diyl-O-, each optionally substituted with one or two groups independently selected from halogen, CN, CF 3 , NR 5 2 , -C 1-4 - alkyl, -S(O) 2 R 5 or -OR 5 , wherein R 2 is connected to R 50 by a C ring atom;
- G 1 , G 2 and G 3 are CR 4 and R 4 is H:
- D is selected from the group consisting of thiazolyl, 1,3,4-thiadiazolyl, 1,2,4- thiadiazolyl, each optionally substituted with one or two groups selected from halogen, CF 3 , or optionally substituted Ci -4 -alkyl; and
- R 5 is selected from the group consisting of:
- a further embodiment is the compound of embodiment 44, wherein R 2 is phenylene-O-.
- Emodiment 50 is the compound of embodiment 21, wherein:
- X is selected from the group consisting of alkyloxy and cycloalkyloxy
- R 2 is optionally substituted methylene-thiophen-2,5-diyl, phenylene-O- or thiophen-2- yl-5-methylene, wherein R 50 is attached to phenylene or thiophenyl;
- G 1 , G 2 and G 3 are CH;
- D is thiazolyl, optionally substituted with one or two groups selected from halogen, CF 3 , or optionally substituted C 1-4 -alkyl;
- R 5 is selected from the group consisting of -
- V is optionally substituted aryl or optionally substituted heteroaryl.
- Emodiment 51 is the compound of embodiment 21. wherein said compound has one of the following combinations of substituents:
- G 2 is CR 4 or N and R 4 is H, halogen or optionally substituted alkyl, or together G and X are connected to form a cyclic group containing 5-7 atoms, wherein
- 0-2 atoms of said cyclic group are heteroatoms and the remaining atoms of said cyclic group are carbon atoms substituted with alkyl, aryl, cycloalkyl or heteroaryl;
- Substituent 1 is X and: X is selected from the group consisting of aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, aryloxy, heteroaryloxy, alkyloxy, cycloalkyloxy and arylalkyloxy; or
- X is selected from the group consisting of alkyl, cycloalkyl, alkyloxy, cycloalkyloxy and aryloxy; or
- X is selected from the group consisting of alkyloxy and cycloalkyloxy
- Substituent 2 is R 2 and:
- R is optionally substituted and is selected from arylene, heteroarylene, alkylene, cycloalkylene, arylalkylene, alkylarylene, arylene-O-, heteroarylene-O-, alkylene-O-, cycloalkylene-O-, arylalkylene-O-, alkylarylene-O-, arylene-S-, heteroarylene-S-, alkylene-S- , cycloalkylene-S-, arylalkylene-S-, or alkylarylene-S-, wherein R 2 is connected to R 50 by a C atom; or
- R 2 is -E'-E ⁇ -E 4 -, wherein E 4 is connected to R 50 ;
- E 1 is a bond, O or S
- E 2 is a bond or alkylene
- E 3 is optionally substituted Ci ⁇ -alkylene, optionally substituted C 3-S - cycloalkylalkylene, arylene or heteroarylene optionally substituted with one or two groups independently selected from aryl, heteroaryl, cycloalkyl, cycloalkenyl, halogen, CN, CF 3 , NR 5 2. -Ci-4-alkyl, -S(O) 2 R 5 or -OR 5 ; wherein, when both E 1 and E 2 are a bond, together they form a single bond;
- R 3 is optionally substituted alkyl or cycloalkyl
- E 4 is a bond or alkylene
- R" is selected from the group consisting of phenyl ene-O-, m ethyl ene-phenylene-O-, phenylene-methylene-0-, furan-2-yl-5-methylene, thiophen-2-yl-5-methylene.
- Substituent 3 is G 1 and: G 1 is N; or G 1 is CR 4 and R 4 is H, halogen or optionally substituted alkyl; Substituent 4 is G 3 and: G 3 is N; or G J is CR 4 and R 4 is H, halogen or optionally substituted alkyl;
- Substituent 5 is D and:
- D is selected from a group consisting of heteroaryl or aryl
- D is a heteroaryl having a nitrogen as a ring atom, said heteroaryl comprising a nitrogen ring atom adjacent to a carbon ring atom, wherein said carbon ring atom is connected to the amide nitrogen atom adjacent to D, and wherein said heteroaryl has an additional 0 to 3 heteroatoms independently selected from O, S or N; or
- D is selected from the group consisting of pyridinyl, thiazolyl, 1,3,4-thiadiazolyl, 1 ,2,4-thiadiazolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzothiazolyl and 5,6-dihydro-4H-cyclopentathiazolyl. each optionally substituted with one or two groups selected from halogen, CF 3 , or optionally substituted C 1-4 - alkyl; or
- D is selected from the group consisting of thiazolyl, 1,3,4-thiadiazolyl. 1,2.4- thiadiazolyl, each optionally substituted with one or two groups selected from halogen, CF 3 , or optionally substituted Ci_4-alkyl; and
- Substituent 6 is R 50 and:
- R 50 is -P(O)( Y 2 R 51 ) R 1 or -P(O)(YR 51 )Y 1 R 51 ;
- Y, Y 1 and Y ⁇ are each independently selected from -O- or -NR 60 -; wherein, when Y 2 is -O- or when Y and Y 1 are both -0-, R 51 attached to -O- is independently selected from -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted -CH 2 -heterocycloakyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, -C(R 52 ) 2 OC(O)NR 52 2 .
- R 51 attached to -NR 60 - is independently selected from -H, -[C(R 52 ) 2 ] r -COOR 53 .
- R 51 attached to -O- is independently selected from -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH 2 -heterocycloakyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl.
- R 51 attached to -NR 60 - is independently selected from -H, -[C(R 52 ) 2 ] r -COOR 53 , -C(R 54 ) 2 COOR 53 , -[C(R 52 ) 2 ] r -C(O)SR 53 , and -cycloalkylene-COOR 53 , wherein if both R 51 are alkyl.
- R 51 and R 51 together form a cyclic group comprising -alkyl-S-S -alkyl-. or R 51 and R 31 together are the group
- V, W. and W * are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl. heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1 -alkynyl, and
- Z is -CHR 52 OH, -CHR 52 OC(O)R 53 ,
- W and W are as defined above and together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0 - 1 atoms are heteroatoms and the remaining atoms are carbon; or
- W and Z are as defined above and together V and W are connected via an additional 3 carbon atoms to form an optionally substituted cyclic group containing 6 carbon atoms or carbon substituted by hydrogen and substituted with one substituent selected from hydroxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy or aryloxycarbonyloxy which is attached to one of said carbon atoms that is three atoms from a Y attached to the phosphorus; or
- V and W are as defined above and together Z and W are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or
- V and Z are as defined above and together W and W are connected via an additional 2-5 atoms to form a cyclic group, wherein 0-2 atoms are heteroatoms and the remaining atoms are carbon, where V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl:
- R 52 is R 53 or -H
- R 53 is alkyl, aryl, heterocycloalkyl or aralkyl
- R 54 is independently selected from -H or alkyl, or together R 54 and R 54 form a cycloalkylene group;
- R 6 is -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, lower acyl, C] -6 - perfluoroalkyl or NH(CR 55 R 55 ) f CH 3 ; r is an integer 2 or 3; f is an integer 0, 1 or 2; wherein, V. Z, W, W are not all -H, and when Z is -R 52 , then at least one of V, W. and W is not -H. alkyl. aralkyl, or heterocycloalkyl; or
- R 30 is selected from the group consisting of
- V is optionally substituted aryl or optionally substituted heteroaryl
- R 56 is -C]-C 12 alkyl, -C 2 -C 12 alkenyl, -C 2 -C 12 alkynyl, -(CR 37 2 ) n aryl, -(CR 57 2 ) n cycloalkyl.
- each R 57 is independently selected from the group consisting of hydrogen, optionally substituted -C 1 -C 4 alkyl, halogen, optionally substituted -0-Ci-C 4 alkyl, -OCF 3 , optionally substituted -S-C 1 -C 4 alkyl, -NR 58 R 59 , optionally substituted -C 2 -C 4 alkenyl, and optionally substituted -C 2 -C 4 alkynyl; with the proviso that when one R 57 is attached to C through an O, S, or N atom, then the other R 57 attached to the same C is a hydrogen, or attached via a carbon atom;
- R 58 is selected from hydrogen and optionally substituted -Ci-C 4 alkyl
- R 59 is selected from the group consisting of hydrogen and optionally substituted -C 1 -C 4 alkyl, optionally substituted -C(O)-C 1 -C 4 alkyl and -C(O)H; or
- R 50 is -P(O)(OH) 2 , -P(O)[-OCH 2 OC(OH-butyl] 2 .
- R 50 is selected from the group consisting of -
- a further embodiment is the compound of embodiment 51, wherein: Substituent 1 is X and:
- X is selected from the group consisting of aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, aryloxy, heteroaryloxy, alkyloxy, cycloalkyloxy and arylalkyloxy;
- Substituent 2 is R 2 and:
- R is optionally substituted and is selected from arylene, heteroarylene, alkylene, cycloalkylene, arylalkylene, alkylarylene, arylene-O-, heteroarylene-O-, alkylene-O-, cycloalkylene-O-, arylalkylene-O-, alkylarylene-O-, arylene-S-, heteroarylene-S-, alkylene-S- , cycloalkylene-S-, arylalkylene-S-, alkylarylene-S-, wherein R 50 is connected to R 2 by a carbon atom;
- Substituent 3 is G 1 and: G 1 is N; or G 1 is CR 4 and R 4 is H, halogen or optionally substituted alkyl;
- Substituent 4 is G 3 and: G 3 is N; or G 3 is CR 4 and R 4 is H, halogen or optionally substituted alkyl;
- Substituent 5 is D and:
- D is selected from a group consisting of heteroaryl or aryl; or
- Substituent 6 is R 50 and:
- R 50 is -P(O)( Y 2 R 51 ) R 1 or -P(O)(YR 3 OY 1 R 51 ;
- Y, Y 1 and Y 2 are each independently selected from -O- or -NR 60 -; wherein, when Y 2 is -O- or when Y and Y 1 are both -O-, R 31 attached to -O- is independently selected from -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted -CEb-heterocycloakyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, -C(R 52 ) 2 OC(O)NR 52 2 , -NR 52 -C(O)-R 53 , -C(R 52 ) 2 -OC(O)R 53 , -C(R 52 ) 2 -O -C(O)OR 53 , -C(R 52 ) 2 OC(O)SR 53 , -alkyl-S-C(O)R 53 , -alky
- V, W, and W are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl, and
- Z is -CHR 52 OH, -CHR 52 OC(O)R 53 ,
- W and W are as defined above and together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0 - 1 atoms are heteroatoms and the remaining atoms are carbon; or
- W and Z are as defined above and together V and W are connected via an additional 3 carbon atoms to form an optionally substituted cyclic group containing 6 carbon atoms or carbon substituted by hydrogen and substituted with one substituent selected from hydroxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy or aryloxycarbonyloxy which is attached to one of said carbon atoms that is three atoms from a Y attached to the phosphorus; or
- V and W are as defined above and together Z and W are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or
- V and Z are as defined above and together W and W are connected via an additional 2-5 atoms to form a cyclic group, wherein 0-2 atoms are heteroatoms and the remaining atoms are carbon, where V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
- R 52 is R 53 or -H
- R 53 is alkyl, aryl, heterocycloalkyl or aralkyl
- R 54 is independently selected from -H or alkyl, or together R 54 and R 54 form a cycloalkylene group;
- R 60 is -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, lower acyl, Ci -6 - perfluoroalkyl or NH(CR 55 R 55 )fCH 3 ; r is an integer 2 or 3 ; f is an integer 0, 1 or 2; wwhheerreeiinn,, VV,, ZZ,, WW,, WW are not all -H, and when Z is -R 37 , then at least one of V, W, and W is not -H, alkyl, aralkyl, or heterocycloalkyl.
- a further embodiment is the compound of embodiment 51, wherein: Substituent 1 is X and:
- X is selected from the group consisting of alkyl, cycloalkyl, alkyloxy, cycloalkyloxy and aryloxy;
- Substituent 2 is R 2 and:
- R 2 is -E'-E 2 -E 3 -E 4 -, wherein E 4 is connected to R 50 ;
- E 1 is a bond, O or S
- E 2 is a bond or alkylene
- E' is optionally substituted Ci-4-alkylene, optionally substituted C 3-8 - cycloalkylalkylene, arylene or heteroarylene optionally substituted with one or two groups independently selected from aryl, heteroaryl, cycloalkyl, cycloalkenyl, halogen, CN, CF 3 , NR 5 2, -C 1-4 -alkyl, -S(O) 2 R 5 or -OR 5 ; wherein, when both E 1 and E 2 are a bond, together they form a single bond;
- R 3 is optionally substituted alkyl or cycloalkyl
- E 4 is a bond or alkylene
- Substituent 3 is G 1 and: G 1 is N; or G 1 is CR 4 and R 4 is H, halogen or optionally substituted alkyl;
- Substituent 4 is G ⁇ and: G 3 is N; or G 3 is CR and R 4 is H, halogen or optionally substituted alkyl;
- Substituent 5 is D and:
- D is a heteroaryl having a nitrogen as a ring atom, said heteroaryl comprising a nitrogen ring atom adjacent to a carbon ring atom, wherein said carbon ring atom is connected to the amide nitrogen atom adjacent to D, and wherein said heteroaryl has an additional 0 to 3 heteroatoms independently selected from O, S or N; and
- Substituent 6 is R 50 and:
- R D is selected from the group consisting of
- V is optionally substituted aryl or optionally substituted heteroaryl
- R 56 is -C 1 -C 12 alkyl, -C 2 -C 12 alkenyl, -C 2 -Ci 2 alkynyl, -(CR D7 2 ) n aryl, -(CR 57 2 ) n cycloalkyl, or -(CR 37 2 ) n heterocycloalkyl, each optionally substituted; each R 57 is independently selected from the group consisting of hydrogen, optionally substituted -Ci-C 4 alkyl, halogen, optionally substituted -0-Ci-C 4 alkyl, -OCF 3 , optionally substituted -S-Ci-C 4 alkyl, -NR 58 R 59 , optionally substituted -C 2 -C 4 alkenyl, and optionally substituted -C 2 -C 4 alkynyl; with the proviso that when one R 37 is attached to C through an O, S, or N atom, then the other R 57 attached to the
- R is selected from hydrogen and optionally substituted -Ci-C 4 alkyl
- R 59 is selected from the group consisting of hydrogen and optionally substituted -C r C 4 alkyl, optionally substituted -C(O)-Ci-C 4 alkyl and -C(O)H.
- a further embodiment is the compound of embodiments 51, 52 or 53, wherein G 1 , G 2 and G 3 are CR 4 and R 4 is H, halogen or optionally substituted alkyl.
- a further embodiment is the compound of embodiment 54, wherein R is H.
- a further embodiment is the compound of embodiments 51, 52, 53, 54 or 55, wherein R 50 is - P(O)(OH) 2 , -P(O)[-OCH 2 OC(O)-r-butyl] 2 , -P(O)[-OCH(CH 3 )OC(O)-f-butyl] 2 , -P(O)[-OCH( CH 3 )OC(O)O-/-propyl] 2 , -P(O)[-OCH 2 OC(O)O-z-propyl] 2 , -P(O)[-OCH 2 OC(O)O-ethylJ 2 , -P( O) [-N(H)CH(CH 3 )C(O)OCH 2 CH 3 J 2 , -P(O)[-N(H)C(CH 3 ) 2 C(O)OCH 2 CH 3 ] 2 , -P(0)[-0CH(
- a further embodiment is the compound of embodiments 51, 52, 53, 54, 55 or 56, wherein
- R 50 is selected from the group consisting of -
- a further embodiment is the compound of embodiments 51. 52. 53, 54, 55. 56 or 57. wherein X is selected from the group consisting of alkyloxy and cycloalkyloxy.
- a further embodiment is the compound of embodiments 51, 52, 53, 54. 55. 56, 57 or 58, wherein R 2 is selected from the group consisting of phenyl ene-O-, methylene-phenylene-O-, phenylene-methylene-O-, furan-2-yl-5-methylene, thiophen-2-yl-5- methylene, pyridin-diyl-O-, pyrimidin-diyl-O-, pyridazin-diyl-O- and pyrazin-diyl-O-.
- R 50 is connected to R 2 by a carbon atom.
- a further embodiment is the compound of embodiment 59, wherein R is optionally substituted methylene-thiophen-2,5-diyl, phenylene-O- or thiophen- 2-yl-5 -methylene, wherein R 50 is connected to the phenylene or thiophenyl group.
- a further embodiment is the compound of embodiments 51 , 52, 53, 54, 55, 56, 57, 58, 59 or 60, wherein D is selected from the group consisting of pyridinyl, thiazolyl, ⁇ ,3 ; 4-thiadiazolyl, 1 ,2,4-thiadiazolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, pyrazinyl, pyridazinyl, pyrimidiny], benzothiazolyl and 5,6-dihydro-4H-cyelopentatbiazolyl. each optionally substituted with one or two groups selected from halogen, CF 3 , or optionally substituted
- a further embodiment is the compound of embodiment 61, wherein D is selected from the group consisting of thiazolyl, 1,3,4-thiadiazolyl, and 1,2,4- thiadiazolyl, each optionally substituted with one or two groups selected from halogen, CF 3 . or optionally substituted C]. 4 -alkyl.
- a further embodiment is a pharmaceutical composition comprising a compound of any one of embodiments 1-62 and a pharmaceutically acceptable excipient.
- a further embodiment is a method of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, said method comprising the step of administering to an animal a therapeutically effective amount of a compound of embodiments 1-62, compositions thereof, or pharmaceutically acceptable salts or prodrugs thereof.
- a further embodiment is the method of embodiment 64, wherein said disease or condition is Type 1 diabetes.
- a further embodiment is the method of embodiment 64, wherein said disease or condition is Type 2 diabetes.
- a further embodiment is the method of embodiment 64, wherein said disease or condition is impaired glucose tolerance.
- a further embodiment is the method of embodiment 64, wherein said disease or condition is insulin resistance
- a further embodiment is the method of embodiment 64, wherein said disease or condition is hyperglycemia
- a further embodiment is the method of embodiment 64, wherein said disease or condition is postprandial hyperglycemia.
- a further embodiment is the method of embodiment 64, wherein said disease or condition is fasting hyperglycemia.
- a further embodiment is the method of embodiment 64, wherein said disease or condition is accelerated gluconeogenesis.
- a further embodiment is the method of embodiment 64, wherein said disease or condition is excessive hepatic glucose output.
- a further embodiment is the method of embodiment 64, wherein said disease or condition is hyperinsulinemia.
- a further embodiment is the method of embodiment 64, wherein said disease or condition is Metabolic Syndrome X.
- compositions comprising a compound of the present invention.
- Another aspect of the present invention are single enantiomers or diasteromers of a compound of the present invention.
- compositions comprising an enantiomer of a compound of the present invention.
- a single enantiomer is >60%, >70%, >80%, >85%. >90%, >91%, >92%, >93%, >94%, >95% , >96%, >97%, >98% or >99% enriched as compared to the total percentage of all other enantiomers of the same compound present in the composition.
- Salts of compounds of the present invention include an inorganic base addition salt such as sodium, potassium, lithium, calcium, magnesium, ammonium, aluminum salts or organic base addition salts, or an inorganic acid addition salt such as HBr, HCl, sulfuric, nitric, or phosphoric acid addition salts or an organic acid addition salt such as acetic, propionic, pyruvic, malanic, succinic, malic, maleic, fumaric, tartaric, citric, benzoic, methanesulfonic, ethanesulforic, stearic or lactic acid addition salt.
- an inorganic base addition salt such as sodium, potassium, lithium, calcium, magnesium, ammonium, aluminum salts or organic base addition salts
- an inorganic acid addition salt such as HBr, HCl, sulfuric, nitric, or phosphoric acid addition salts
- an organic acid addition salt such as acetic, propionic, pyruvic, malanic, succinic, mal
- anhydrates, hydrates and solvates of compounds of the present invention and pharmaceutical compositions comprising a pharmaceutically acceptable anhydrates, hydrates and solvates of the present invention. Included are an anhydrate, hydrate or solvate of a free form or salt of a compound of the present invention. Hydrates include, for example, a hemihydrate, monohydrate, dihydrate, trihydrate, quadrahydrate. pentahydrate, sesquihydrate.
- Another aspect provides for the use of a compound of the present invention for the manufacture of a medicament for treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated.
- Another aspect provides for the use of a compound of the invention for the manufacture of a medicament for treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition responsive to decreased hepatic glucose production or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount a compound of the invention, or a pharmaceutically acceptable salt or prodrugs thereof.
- Another aspect provides for methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated.
- Another aspect provides for methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition responsive to decreased hepatic glucose production or responsive to lowered blood glucose levels, the method comprising the step of administering to an animal a therapeutically effective amount a compound of the invention, or a pharmaceutically acceptable salt or prodrugs thereof.
- Another aspect provides for methods for treating, preventing, delaying the time to onset or reducing the risk for the development or progression of Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount a compound of the invention.
- Another aspect provides for methods for treating, preventing, delaying the time to onset or reducing the risk for the development or progression of Type 1 diabetes, the method comprising the step of administering to an animal a therapeutically effective amount a compound of the invention.
- Another aspect provides for methods for treating, preventing, delaying the time to onset or reducing the risk for the development or progression of impaired glucose tolerance, the method comprising the step of administering to an animal a therapeutically effective amount a compound of the invention.
- Another aspect provides for methods for treating, preventing, delaying the time to onset or reducing the risk for the development or progression of insulin resistance, the method comprising the step of administering to an animal a therapeutically effective amount a compound of the invention.
- hyperglycemia is postprandial hyperglycemia.
- the hyperglycemia is fasting hyperglycemia.
- Another aspect provides for methods for treating, preventing, delaying the time to onset of or reducing the risk for the development or progression of accelerated gluconeogenesis, the method comprising the step of administering to an animal a therapeutically effective amount a compound of the invention.
- Another aspect provides for methods for treating, preventing, delaying the time to onset of or reducing the risk for the development or progression of increased or excessive (greater than normal levels) hepatic glucose output, the method comprising the step of administering to an animal a therapeutically effective amount a compound of the invention.
- Another aspect provides for methods for treating, preventing, delaying the time to onset of or reducing the risk for the development or progression of hyperinsulinemia, the method comprising the step of administering to an animal a therapeutically effective amount a compound of the invention.
- Another aspect provides for methods for treating, preventing, delaying the time to onset of or reducing the risk for the development or progression of hyperlipidemia, the method comprising the step of administering to an animal a therapeutically effective amount a compound of the invention.
- Another aspect provides for methods for treating, preventing, delaying the time to onset of or reducing the risk for the development or progression of dyslipidemia, the method comprising the step of administering to an animal a therapeutically effective amount a compound of the invention.
- Another aspect provides for methods for treating, preventing, delaying the time to onset of or reducing the risk for the development or progression of hypercholesterolemia, the method comprising the step of administering to an animal a therapeutically effective amount a compound of the invention.
- aspects provide for methods for treating, preventing, delaying the time to onset of or reducing the risk for the development or progression of atherosclerosis, obesity, or Metabolic Syndrome X.
- the method comprising the step of administering to an animal a therapeutically effective amount a compound of the invention.
- compounds of the invention are administered in a total daily dose of 0.01 to 2500 mg. In one aspect the range is about 1 mg to about 1000 mg. In one aspect the range is about 1 mg to about 500 mg. In one aspect the range is about 10 mg to about 500 mg. The dose may be administered in as many divided doses as is convenient or necessary. In another aspect, compounds of the invention are administered in a unit dose of a range between 0.01 to 1000 mg. In one aspect the range is about 0.1 mg to about 500 mg. In one aspect the range is about 0.1 mg to about 100 mg. In one aspect the range is about 1 mg to about 1000 mg. In one aspect the range is about 1 mg to about 500 mg. In one aspect the range is about 1 mg to about 100 mg.
- the range is about 1 mg to about 10 mg. In one aspect the range is about 10 mg to about 1000 mg. In one aspect the range is about 10 mg to about 500 mg. In one aspect the range is about 10 mg to about 100 mg. In one aspect, the unit dose is 10 mg. In one aspect, the unit dose is 25 mg. In one aspect the unit dose is 50 mg. In one aspect, the unit dose is 75 mg. In one aspect, the unit dose is 100 mg. In one aspect, the unit dose is 150 mg. In one aspect, the unit dose is 200 mg. In one aspect, the unit dose is 250 mg. In one aspect, the unit dose is 300 mg. In one aspect, the unit dose is 400 mg. In one aspect the unit dose is 500 mg. In one aspect, the unit dose is 600 mg. In one aspect, the unit dose is 700 mg. In one aspect the unit dose is 800 mg. In one aspect, the unit dose is 900 mg. In one aspect, the unit dose is 1000 mg.
- the compound is administered QD (once a day). In another aspect the compound is administered BID (twice a da)'). In another aspect the compound is administered TID (three times a day). In another aspect the compound is administered QID (four times a day). In one aspect the compound is administered before a meal. In one aspect the compound is administered after a meal. In one aspect the compound is administered in the morning hours. In one aspect the compound is administered upon awaking in the morning. In one aspect the compound is administered in the evening hours. In one aspect the compound is administered at bedtime in the evening.
- Compounds of this invention may be used in combination with other pharmaceutical agents.
- the compounds may be administered as a daily dose or an appropriate fraction of the daily dose (e.g., bid). Administration of the compound may occur at or near the time in which the other pharmaceutical agent is administered or at a different time.
- the compounds of this invention may be used in a multidrug regimen, also known as combination or 'cocktail ' therapy, wherein, multiple agents may be administered together, may be administered separately at the same time or at different intervals, or administered sequentially.
- the compounds of this invention may be administered after a course of treatment by another agent, during a course of therapy with another agent, administered as part of a therapeutic regimen, or may be administered prior to therapy by another agent in a treatment program.
- the compounds may be administered by a variety of means including orally, parenterally, by inhalation spray, topically, or rectally in formulations containing pharmaceutically acceptable carriers, adjuvants and vehicles.
- parenteral as used here includes subcutaneous, intravenous, intramuscular, and intraarterial injections with a variety of infusion techniques.
- Intraarterial and intravenous injection as used herein includes administration through catheters. Intravenous administration is generally preferred.
- Pharmaceutically acceptable salts include acetate, adipate, besylate, bromide, camsylate, chloride, citrate, edisylate, estolate, fumarate, gluceptate, gluconate, glucoranate, hippurate, hyclate, hydrobromide, hydrochloride, iodide, isethionate, lactate, lactobionate, maleate, mesylate, methylbromide, methylsulfate, napsylate, nitrate, oleate, palmoate, phosphate, polygalacturonate, stearate, succinate, sulfate, subsalicylate, tannate, tartrate, terphthalate, tosylate. and triethiodide.
- compositions containing the active ingredient may be in any form suitable for the intended method of administration.
- tablets, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs may be prepared.
- Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents including sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide a palatable preparation.
- Tablets containing the active ingredient in admixture with non-toxic pharmaceutically acceptable excipient which are suitable for manufacture of tablets are acceptable.
- excipients may be, for example, inert diluents, such as calcium or sodium carbonate, lactose, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- One aspect relates to the administration of a pharmaceutically acceptable composition of the present invention by controlled- or delayed-release means.
- Controlled-release pharmaceutical products have a common goal of improving drug therapy over that achieved by their non-controlled release counterparts.
- a variety of known controlled- or extended-release dosage forms, formulations, and devices can be adapted for use with the crystalline forms of the invention. Examples include, but are not limited to, those described in U.S. Pat. Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598, 123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5, 639,476; 5,354,556; 5,733,566; and 6,365,185; each of which is incorporated herein by reference.
- dosage forms can be used to provide delayed or controlled- release of one or more active ingredients using, for example, hydroxypropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems (such as OROS, Alza Corporation, Mountain View, Calif. USA), multilayer coatings, microparticles, liposomes, or microspheres or a combination thereof to provide the desired release profile in varying proportions.
- ion exchange materials can be used to prepare immobilized, adsorbed co- crystals and thus effect controlled delivery of the drug. Examples of specific anion exchangers include, but are not limited to, Duolite A568 and Duolite AP 143 (Rohm & Haas, Spring House, PA, USA).
- One aspect of the invention encompasses a unit dosage form which comprises a pharmaceutically acceptable composition comprising a crystalline form of a compound of the present invention and one or more pharmaceutically acceptable excipients or diluents, wherein the pharmaceutical composition, medicament or dosage forms is formulated for controlled-release.
- the dosage form utilizes an osmotic drug delivery system.
- OROS osmotic drug delivery system
- This technology can readily be adapted for the delivery of compounds and compositions of the invention.
- Various aspects of the technology are disclosed in U.S. Pat. Nos. 6, 375, 978; 6,368,626 ; 6,342.249; 6,333,050; 6,287,295; 6, 283,953; 6,270,787; 6,245,357; and 6,132,420: each of which is incorporated herein by reference.
- OROS that can be used to administer compounds and compositions of the invention
- OROS include, but are not limited to, the OROS; Push- Pull, Delayed Push-Pull, Multi-Layer Push- Pull, and Push-Stick Systems, all of which are well known. See, e.g., www. alza.com.
- Additional OROS systems that can be used for the controlled oral delivery of compounds and compositions of the invention include OROS- CT and L-OROS (Id.; see also, Delivery Times, vol. II, issue II (Alza Corporation).
- OROS oral dosage forms are made by compressing a drug powder (e.g. a crystalline form selected from Forms A-D) into a hard tablet, coating the tablet with cellulose derivatives to form a semi-permeable membrane, and then drilling an orifice in the coating (e.g., with a laser).
- a drug powder e.g. a crystalline form selected from Forms A-D
- Kim Cherug-ju, Controlled Release Dosage Form Design, 231- 238 (Technomic Publishing, Lancaster, PA: 2000).
- the advantage of such dosage forms is that the delivery rate of the drug is not influenced by physiological or experimental conditions. Even a drug with a pH-dependent solubility can be delivered at a constant rate regardless of the pH of the delivery medium. But because these advantages are provided by a build-up of osmotic pressure within the dosage form after administration, conventional OROS drug delivery systems cannot be used to effectively deliver drugs with low water solubility. Id. at 234.
- a specific dosage form of the invention comprises: a wall defining a cavity, the wall having an exit orifice formed or formable therein and at least a portion of the wall being semipermeable; an expandable layer located within the cavity remote from the exit orifice and in fluid communication with the semipermeable portion of the wall; a dry or substantially dry state drug layer located within the cavity adjacent to the exit orifice and in direct or indirect contacting relationship with the expandable layer; and a flow-promoting layer interposed between the inner surface of the w r all and at least the external surface of the drug layer located within the cavity, wherein the drug layer comprises a crystalline form of a compound of the present invention. See U.S. Pat. No. 6,368,626, the entirety of which is incorporated herein by reference.
- Another specific dosage form of the invention comprises: a wall defining a cavity, the wall having an exit orifice formed or formable therein and at least a portion of the wall being semipermeable; an expandable layer located within the cavity remote from the exit orifice and in fluid communication with the semipermeable portion of the wall; a drug layer located within the cavity adjacent the exit orifice and in direct or indirect contacting relationship with the expandable layer; the drug layer comprising a liquid, active agent formulation absorbed in porous particles, the porous particles being adapted to resist compaction forces sufficient to form a compacted drug layer without significant exudation of the liquid, active agent formulation, the dosage form optionally having a placebo layer between the exit orifice and the drug layer, wherein the active agent formulation comprises a crystalline form of a compound of the present invention. See U. S. Pat. No. 6,342,249, the entirety of which is incorporated herein by reference.
- a pharmaceutical composition or medicament comprising a crystalline form of a compound of the present invention is administered transdermally.
- TD transdermal
- a "pill-and-patch" strategy can be taken, where only a fraction of the daily dose is delivered through the skin to generate basal systemic levels, onto which oral therapy is added.
- Formulations for oral use may be also presented as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent, for example calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
- an inert solid diluent for example calcium phosphate or kaolin
- an oil medium such as peanut oil, liquid paraffin or olive oil.
- Aqueous suspensions of the invention contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients include a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan monoo
- the aqueous suspension may also contain one or more preservatives such as ethyl or n-propyl p-hydroxy-benzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose or saccharin.
- Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as arachid oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
- the oral suspensions may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol.
- Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation.
- These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
- Dispersible powders and granules of the invention suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those disclosed above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
- the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
- the oily phase may be a vegetable oil. such as olive oil or arachid oil, a mineral oil, such as liquid paraffin, or a mixture of these.
- Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of these partial esters with ethylene oxide, such as polyoxy ethylene sorbitan monooleate.
- the emulsion may also contain sweetening and flavoring agents.
- Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
- sweetening agents such as glycerol, sorbitol or sucrose.
- Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
- compositions of the invention may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension.
- a sterile injectable preparation such as a sterile injectable aqueous or oleaginous suspension.
- This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1 ,3-butane-diol or prepared as a lyophilized powder.
- the acceptable vehicles and solvents that may be employed are water. Ringer ' s solution and isotonic sodium chloride solution.
- sterile fixed oils may conventionally be employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid may likewise be used in the preparation of injectables.
- formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
- the active ingredient may also be administered as a bolus, electuary or paste.
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free flowing form such as a powder or granules, optionally mixed with a binder (e.g.. povidone, gelatin, hydroxypropylm ethyl cellulose), lubricant, inert diluent, preservative, disintegrant (e.g., sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose) surface active or dispersing agent.
- Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropyl methylee ⁇ lulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach. This is particularly advantageous with the compounds of Formula I when such compounds are susceptible to acid hydrolysis.
- Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
- Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
- Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
- Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- the formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
- Injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- Formulations suitable for parenteral administration may be administered in a continuous infusion manner via an indwelling pump or via a hospital bag. Continuous infusion includes the infusion by an external pump. The infusions may be done through a Hickman or PICC or any other suitable means of administering a formulation either parenterally or i.v.
- Preferred unit dosage formulations are those containing a daily dose or unit, daily sub-dose, or an appropriate fraction thereof, of a drug.
- the specific dose level for any particular patient will depend on a variety of factors including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the individual being treated; the time and route of administration; the rate of excretion; other drugs which have previously been administered; and the severity of the particular disease undergoing therapy, as is well understood by those skilled in the art.
- Prodrugs can be introduced at different stages of the synthesis. Most often these prodrugs are made from the phosphonic acids of compounds of the invention because of their lability.
- Phosphonic acids of compounds of the invention can be alkylated with electrophiles such as alkyl halides and alkyl sulfonates under nucleophilic substitution conditions to give phosphonate esters.
- acyloxyalkyl prodrugs of compounds of the invention can be prepared by direct alkylation of compounds of Formula I with an appropriate acyloxyalkyl halide (e.g., Cl, Br, I; Phosphorus Sulfur 54:143 (1990); Synthesis 62 (1988)) in the presence of a suitable base (e.g., pyridine.
- a suitable base e.g., pyridine.
- acyloxyalkyl halides includes but is not limited to acetate, propionate, isobutyrate. pivalate, benzoate, carbonate and other carboxylates.
- Dimethylformamide dialkyl acetals can also be used for the alkylation of phosphonic acids (Collect. Czech Chem. Commu. 59:1853 (1994)).
- Compounds of the invention wherein the prodrug moiety comprises a cyclic carbonate, a lactone or a phthalidyl group can also be synthesized by direct alkylation of the free phosphonic acids with appropriate halides in the presence of a suitable base such as NaH or diisopropylethylamine (J. Med. Chem. 35:1372 (1995); J Med. Chem. 37:1857 (1994); J. Pharm. ScL 75:180 (1987)).
- these phosphonate prodrugs can be synthesized by the reactions of the corresponding dichlorophosphonates and an alcohol (Collect Czech Chem. Commun. 59:1853 (1994)).
- a dichlorophosphonate is reacted with substituted phenols and arylalkyl alcohols in the presence of a base such as pyridine or TEA to give the compounds of the invention wherein the prodrug moiety is an aryl group (J. Med. Chem. 39:4109 (1996); J. Med. Chem. 38:1372 (1995); J Med. Chem. 37:498 (1994)) or an arylalkyl group (J Chem. Soc. Perkin Trans. 1 35:2345 (1992)).
- the disulfide-containing prodrugs can be prepared from a dichlorophosphonate and 2- hydroxyethyldisulfide under standard conditions. Dichlorophosphonates are also useful for the preparation of various phosphonamides as prodrugs.
- treatment of a dichlorophosphonate with ammonia gives both a monophosphonamide and a diphosphonamide
- treatment of a dichlorophosphonate with l-amino-3- ⁇ ropanol gives a cyclic 1,3-propylphosphonamide
- treatment of a chlorophosphonate monophenyl ester with an amino acid ester in the presence of a suitable base gives a substituted monophenyl monophosphonam i date .
- Such reactive dichlorophosphonates can be generated from the corresponding phosphonic acids with a chlorinating agent (e.g., thionyl chloride, J. Med. Chem. 1857 (1994); oxalyl chloride, Tetrahedron Lett. 37:3261 (1990); phosphorous pentachloride, Synthesis 490 (1974)).
- a dichlorophosphonate can be generated from its corresponding disilyl phosphonate esters (Synth. Commu. 77:1071 (1987)) or dialkyl phosphonate esters (Tetrahedron Lett. 24:4405 (1983); Bull. Soc. Chim. 730:485 (1993)).
- Compounds of the invention can be mixed phosphonate ester (e.g., phenyl and benzyl esters. or phenyl and acyloxyalkyl esters) including the chemically combined mixed esters such as phenyl and benzyl combined prodrugs reported in Bioorg. Med. Chem. Lett. 7:99 (1997).
- mixed phosphonate ester e.g., phenyl and benzyl esters. or phenyl and acyloxyalkyl esters
- Dichlorophosphonates are also useful for the preparation of various phosphonamides as prodrugs.
- a dichlorophosphonate with an amine e.g. an amino acid alkyl ester such as L-alanine ethyl ester
- a suitable base e.g. triethylamine. pyridine, etc.
- treatment of a dichlorophosphonate with l-amino-3-propanol gives a cyclic 1,3-propylphosphonamide
- treatment of a chlorophosphonate monophenyl ester with an amino acid ester in the presence of a suitable base gives a substituted monophenyl monophosphonamidate.
- the SATE (S-acetyl thioethyl) prodrugs can be synthesized by the coupling reaction of the phosphonic acid compounds of the invention and S-acyl-2-thioethanol in the presence of DCC, EDCl or PyBOP (J. Med. Chem. 59:1981 (1996)).
- Cyclic phosphonate esters of substituted 1,3-propane diols can be synthesized by either reactions of the corresponding dichlorophosphonate with a substituted 1,3 -propanediol or coupling reactions using suitable coupling reagents (e.g., DCC, EDCI, PyBOP; Synthesis 62 (1988)).
- the reactive dichlorophosphonate intermediates can be prepared from the corresponding acids and chlorinating agents such as thionyl chloride (J Med. Chem. 1857 (1994)), oxalyl chloride (Tetrahedron Lett. 5i:3261 (1990)) and phosphorus pentachloride (Synthesis 490 (1974)).
- dichlorophosphonatcs can also be generated from disilyl esters (Synth. Commun. 77:1071 (1987)) and dialkyl esters (Tetrahedron Lett. 24:4405 (1983); Bull. Soc. Chim. Fr., /30:485 (1993)).
- these cyclic phosphonate esters of substituted 1,3-propane diols are prepared from phosphonic acids by coupling with diols under Mitsunobu reaction conditions (Synthesis 1 (1981); J.Org. Chem. 52:6331 (1992)), and other acid coupling reagents including, but not limited to. carbodiimides (Collect. Czech. Chem. Commun. 59:1853 (1994); Bioorg. Med. Chem. Lett. 2:145 (1992); Tetrahedron Lett. 29:1189 (1988)), and benzotriazolyloxytris-(dimethylamino) phosphonium salts (Tetrahedron Lett. 34:6743 (1993)).
- Phosphonic acids also undergo cyclic prodrug formation with cyclic acetals or cyclic ortho esters of substituted propane-l,3-diols to provide prodrugs as in the case of carboxylic acid esters (HeIv. Chim. Acta. 48: 1746 (1965)).
- cyclic acetals or cyclic ortho esters of substituted propane-l,3-diols to provide prodrugs as in the case of carboxylic acid esters (HeIv. Chim. Acta. 48: 1746 (1965)).
- more reactive cyclic sulfites or sulfates are also suitable coupling precursors to react with phosphonic acid salts. These precursors can be made from the corresponding diols as described in the literature.
- cyclic phosphonate esters of substituted 1,3-propane diols can be synthesized by trans esterification reaction with substituted 1,3-propane diol under suitable conditions.
- Mixed anhydrides of parent phosphonic acids generated in situ under appropriate conditions react with diols to give prodrugs as in the case of carboxylic acid esters (Bull. Chem. Soc. Jpn. 52: 1989 (1979)).
- Aryl esters of phosphonates are also known to undergo transesterification with alkoxy intermediates (Tetrahedron Lett. 38:2597 (1997); Synthesis 968 (1993)).
- One aspect of the present invention provides methods to synthesize and isolate single isomers of prodrugs of compounds of the invention that are phosphonic acids. Because phosphorus is a stereogenic atom, formation of a prodrug with a substituted-l,3-propane-diol will produce a mixture of isomers. For example, formation of a prodrug with a racemic 1- (V)-substituted-l,3-propane diol gives a racemic mixture of cis-prodrugs and a racemic mixture of trans-prodrugs.
- the use of the enantioenriched substituted- 1,3- propane diol with the R-configuration gives enantioenriched R-cis-and R-trans-prodrugs.
- These compounds can be separated by a combination of column chromatography and/or fractional crystallization.
- the compounds of the invention can be mixed phosphonate esters (e.g. phenyl benzyl phosphonate esters, phenyl acyloxyalkyl phosphonate esters, phenyl aminoacid esters etc).
- phosphonate esters e.g. phenyl benzyl phosphonate esters, phenyl acyloxyalkyl phosphonate esters, phenyl aminoacid esters etc.
- the chemically combined phenyl-benzyl prodrugs are reported by Meier, et al. Bioorg. Med Chem. Lett, 1997, 7: 99.
- the substituted cyclic propyl phosphonate esters compounds of the invention can be synthesized by reaction of the corresponding dichlorophosphonate and the substituted 1.3- propane diol.
- the following are non-limiting methods to prepare the substituted 1,3-propane diols.
- This step includes various synthetic methods for the preparation of the following types of propane- 1,3 -diols: i) 1 -substituted; ii) 2-substituted; and iii) 1,2- or 1,3-annulated.
- Different groups on the prodrug part of the molecule i.e., on the propane diol moiety can be introduced or modified either during the synthesis of the diols or after the synthesis of the prodrugs.
- 1 ,3-Propanediols useful in the synthesis of compounds in the present invention can be prepared using various synthetic methods. As described in Scheme A, additions of an aryl Grignard to a l-hydroxy-propan-3-al give 1-aryl-substituted 1,3 -propanediols (path a). This method is suitable for the conversion of various aryl halides to l -arylsubstituted-l ,3-propanediols (J. Org. Chem. 1988, 53, 911).
- Conversions of aryl halides to 1 -substituted 1,3 -propanediols can also be achieved using Heck reactions (e.g., couplings with a l,3-diox-4-ene) followed by reductions and subsequent hydrolysis reactions (Tetrahedron Lett. 1992, 33, 6845).
- Various aromatic aldehydes can also be converted to 1 -substituted- 1,3-propanediols using alkenyl Grignard addition reactions followed by hydroboration-oxidation reactions (path b).
- A OR, NR(R), wherein each R is independently selected from groups including alkyl and aralkly(e.g., Bn);
- R' is a protecting group such as Bn, Si(R")(R")-, wherein each R" is independently alkyl or aryl, or -C-O-Me.
- Aldol reactions between an enolate (e.g., lithium, boron, tin enolates) of a carboxylic acid derivative (e.g., tert-butyl acetate) and an aldehyde (e.g., the Evans's aldol reactions) are especially useful for the asymmetric synthesis of enantioenriched 1,3-propanediols.
- an enolate e.g., lithium, boron, tin enolates
- a carboxylic acid derivative e.g., tert-butyl acetate
- an aldehyde e.g., the Evans's aldol reactions
- epoxidation of cinnamyl alcohols using known methods e.g., Sharpless epoxidations and other asymmetric epoxidation reactions
- reduction reactions e.g., using Red- Al
- Enantioenriched 1,3-propanediols can be obtained via asymmetric reduction reactions (e.g., enantioselective borane reductions) of 3-hydroxy-ketones ⁇ Tetrahedron Lett. 1997, 38 761).
- racemic 1,3-propanediols using various methods (e.g., enzymatic or chemical methods) can also give enantioenriched 1,3 -propanediol.
- Propan-3-ols with a 1-heteroaryl substituent e.g., a pyridyl, a quinolinyl or an isoquinolinyl
- a 1-heteroaryl substituent e.g., a pyridyl, a quinolinyl or an isoquinolinyl
- path d acetic anhydride conditions
- Formula I can be prepared from various other 1,3-propanediols (e.g., 2-(hydroxymethyl)-l,3-propanediols) using conventional chemistry (Comprehensive Organic Transformations, VCH, New York, 1989).
- reductions of a trialkoxycarbonylmethane under known conditions give a triol via complete reduction (path a) or a bis(hydroxymethyl)acetic acid via selective hydrolysis of one of the ester groups followed by reduction of the remaining two other ester groups.
- Nitrotriols arc also known to give triols via reductive elimination (path b) (Synthesis 1987, 5. 742).
- a 2-(hydroxymethyl)-l,3-propanediol can be converted to a mono acylated derivative (e.g., acetyl, methoxycarbonyl) using an acyl chloride or an alkyl chloroformate (e.g., acetyl chloride or methyl chloroformate) (path d) using known chemistry (Protective Groups In Organic Synthesis ; Wiley, New York, 1990).
- a mono acylated derivative e.g., acetyl, methoxycarbonyl
- an alkyl chloroformate e.g., acetyl chloride or methyl chloroformate
- Compounds of invention wherein V and Z or V and W are connected by four carbons to form a ring can be prepared from a 1,3-cyclohexanediol.
- cis, czs- 1,3,5-cyclohexanetriol can be modified to give various other 1,3,5-cyclohexanetriols which are useful for the preparations of compounds of Formula I wherein R 51 and R 51 together are
- V and W are connected via 3 atoms to form a cyclic group containing 6 carbon atoms substituted with a hydroxy group. It is envisioned that these modifications can be performed either before or after formation of a cyclic phosphonate 1,3 -propanediol ester.
- Various 1,3-cyclohexanediols can also be prepared using Diels-Alder reactions (e.g., using a pyrone as the diene: Tetrahedron Lett. 1991, 32, 5295).
- 2-Hydroxymethylcyclohexanols and 2-hydroxymethylcyclopentanols are useful for the preparations of compounds of the invention wherein R 51 and R 51 together are
- 1,3-Cyclohexanediol derivatives are also prepared via other cycloaddition reaction methodologies. For example, cycloadducts from the cycloadditon reactions of a nitrile oxide and an olefin can be converted to a 2-ketoethanol derivative which can be further converted to a 1.3-propanediol (including 1,3-cyclohexanediol, 2-hydroxymethylcyclohexanol and 2-hydroxymethylcyclopentanol) using known chemistry (J. Am. Chem. Soc. 1985, 107. 6023).
- Alternativel ⁇ * precursors to 1,3-cyclohexanediol can be made from quinic acid ⁇ Tetrahedron Lett. 1991. 52, 547.
- Select compounds may be prepared from phosphonate esters using known phosphate and phosphonate ester cleavage conditions.
- silyl halides have been used to cleave the various phosphonate esters, followed by mild hydrolysis of the resulting silyl phosphonate esters to give the desired phosphonic acids.
- acid scavengers such as 1,1.1,3-3.3-hexamethyldisilazane, 2,6-lutidine, etc.
- Such silyl halides include, chlorotrimethylsilane (Rabinowitz, J. Org. Chem..
- phosphonate esters can be cleaved under strong acid conditions, (e.g HBr. HCl, etc.) in polar solvents, preferably acetic acid (Moffatt. et al, U.S. Patent 3,524.846, 1970) or water.
- esters can also be cleaved via dichlorophosphonates, prepared by treating the esters with halogenating agents e.g. phosphorus pentachloridc, thionyl chloride, BBr 3 , etc.(Pelchowicz, et al. J Chem. Soc, 1961, 238) followed by aqueous hydrolysis to give phosphonic acids.
- halogenating agents e.g. phosphorus pentachloridc, thionyl chloride, BBr 3 , etc.
- Aryl and benzyl phosphonate esters can be cleaved under hydrogenolysis conditions (Lejczak, et al, Synthesis, 1982, 412; Elliott, et al, J Med.
- Phosphinic acids and phosphonic acid monoesters can be alkylated with electrophiles such as alkyl halides and alkyl sulfonates under nucleophilic substitution conditions to give phosphinate and phosphonate ester prodrugs.
- compounds of Formulas I and II wherein Y 2 R 5 ' is an acyloxyalkyl group can be prepared by direct alkylation of compounds of Formulas I and II wherein Y 2 R 51 is OH with an appropriate acyloxyalkyl halide (e.g., Cl, Br, I; Phosphorus Sulfur 54:143 (1990); Synthesis 62 (1988)) in the presence of a suitable base (e.g., pyridine, TEA, diisopropylethylamine) in suitable solvents such as DMF (J. Med. Chem. 57:1875 (1994)).
- a suitable base e.g., pyridine, TEA, diisopropylethylamine
- suitable solvents such as DMF (J. Med. Chem. 57:1875 (1994)
- the carboxylate component of these acyloxyalkyl halides includes but is not limited to acetate, propionate, isobutyrate, pivalate,
- Dimethylformamide dialkyl acetals can also be used for the alkylation of phosphinic acids and phosphonic acid monoesters (Collect. Czech Chem. Commu. 59:1853 (1994)).
- Compounds of Formulas I and II wherein Y ⁇ R 51 is a cyclic carbonate, a lactone or a phthalidyl group can also be synthesized by direct alkylation of the free phosphonic acids with appropriate halides in the presence of a suitable base such as NaH or diisopropylethylamine (J. Med. Chem. 38:1372 (1995); J Med. Chem. 37:1857 (1994); J Pharm. Sci. 7(5:180 (1987)).
- these phosphinate and phosphonate monoester prodrugs can be synthesized by the reactions of the corresponding chlorophospho(i)nate and an alcohol (Collect Czech Chem. Commun. 59:1853 (1994)).
- a chlorophospho(i)nate is reacted with substituted phenols and arylalkyl alcohols in the presence of a base such as pyridine or TEA to give the compounds of Formula I wherein YR is an aryl group (J. Med. Chem. 39:4109 (1996); J. Med. Chem. 38:1372 (1995); J Med Chem. 37:498 (1994)) or an arylalkyl group (J Chem. Soc. Perkin Trans.
- the disulfide-containing prodrugs can be prepared from a chlorophospho(i)nate and 2- hydroxyethyldisulfide under standard conditions. Chlorophospho(i)nates are also useful for the preparation of various phospho(i)namides as prodrugs. For example, treatment of a chlorophospho(i)nate with ammonia gives the phospho(i)namide.
- Such reactive chlorophospho(i)nates can be generated from the corresponding phosphinic acids and phosphonic acid monoesters with a chlorinating agent (e.g., thionyl chloride, J. Med. C hem. 1857 (1994); oxalyl chloride, Tetrahedron Lett. 31:3261 (1990); phosphorous pentachloride, Synthesis 490 (1974)).
- a chlorophospho(i)nate can be generated from its corresponding silyl phosphinate ester or phosphonic acid monester (Synth. Commu. 17:1071 (1987)) or alkyl phosphinate esters (Tetrahedron Lett. 24:4405 (1983); Bull. Sot: CMm. 750:485 (1993)).
- Chlorophospho(i)nates are also useful for the preparation of various phosphonamides as prodrugs.
- treatment of a chlorophospho(i)nate with an amine e.g. an amino acid alkyl ester such as L-alanine ethyl ester
- a suitable base e.g. triethylamine, pyridine, etc.
- phosphinic acids or phosphonic acid monoesters with an amine e.g. an amino acid alkyl ester such as L-alanine ethyl ester
- an amino acid alkyl ester such as L-alanine ethyl ester
- the SATE (S-acetyl thioethyl) prodrugs can be synthesized by the coupling reaction of the phosphinic acids or phosphonic acid monoesters of Formulas I and II and S-acyl-2- thioethanol in the presence of DCC, EDCl or PyBOP (J. Med. Chem. 3P:1981 (1996)).
- Compounds of Formulas I and II wherein R 50 is -P(O)(Y 2 R 51 )(OR 3 ) and R 3 is C 1 - C 6 alkyl may be prepared from the diester intermediate, used for the synthesis of phosphonic acid, by monosaponification.
- Monohydrolysis of one of the ester groups on the phosphonate may be accomplished by treatment of phosphonate diesters with aqueous alkaline solution such as NaOH. KOH or LiOH at rt or while heating.
- Sodium azide can also be used in DMF (Bioorg. Med. Chem. Lett. 14(13)3559-62 (2004)) to accomplished the monosaponification.
- organic bases such as morpholine or N-methyl-piperazine can be used to hydrolyze one of the phosphonate ester groups (Synth. Comm. 34(2):33l-344 (2004)).
- phosphinic acid group can generally be accomplished according to known methods.
- An efficient w r ay to synthesize phosphinic acid is to convert a phosphonate diester to its corresponding monochloridate-monoester using one of many chlorinating agents such as PCl 5 (Can. J. Chem. 76(3):3 ⁇ 3- ⁇ 8 (1998)), oxalyl chloride (Tetrahedron Lett. 44(12): ⁇ 445-4% (2003)), thionyl chloride ( J Med. Chem. 45(4):919-29 (2002)) or phosgene (Reel. Trav. Chim.
- phosphinic acids can be generated from phosphonic acid monoesters by making the monochloridate-monoester with chlorinating reagents such as thionyl chloride or oxalyl chloride, and introducing the substituent on the phosphorus as above.
- chlorinating reagents such as thionyl chloride or oxalyl chloride
- Cyclic phosphinic acids can be synthesized starting from a 1,2-dicarboxylate-benzene precursor (J Am. Chem. Soc. 1 OT.7001-08 (1979)) which is reduced to the di-benzylic alcohol and brominated with PBr 3 to give the di-benzylic bromide precursor (Synth. Commun. 14(6):507-5l4 (1984)). Double Arbuzov condensation of the di-benzylic bromide with bis(trimethylsilyloxy)phosphine, made from the reaction of ammonium hypophosphite and hexamethyldisilazane, provides the cyclic phosphinate ester (J Org. Chem.
- the di-benzyl bromide precursor can be obtained by bromination of a substituted 1,2-dimethyl benzene with bromine or N-bromosuccinimide (J. Chem. Soc. 3358- 61 (1959)) or direct bromomethylation by reacting formaldehyde and HBr in presence of acetic acid (J Phys. Chem. 108(4):5 ⁇ 45-55 (2004)).
- Compounds of Formula I wherein R 50 is -P(O)(OH) 2 or -P(O)(OH)P 2 may be prepared from phosphonate or phosphinate esters using the known cleavage methods.
- Silyl halides are generally used to cleave various phosphonate or phosphinate esters and give the desired phosphonic or phosphinic acid upon mild hydrolysis of the resulting phosphonate or phosphinate silyl esters.
- acid scavengers e.g., HMDS
- Representative conditions can be found in the Generation of phospho(i)nic acid section in this publication. Methods to form phosphonate monoesters can be found in the Generation of Phosphonic Acid Monoesters section in this publication.
- a phosphonate or phosphinate group generally can be accomplished according to known procedures.
- Compounds of Formula 1 wherein D is nitrogen-containing heteroarylene may be prepared by a number of known methods (Scheme T). For example, the coupling reaction of a phenyl bromide (J. Org. Chem. 1999, 64, 120), iodide (Phosphorus Sulfur 1997, 130, 59) or triflate (J. Org. Chem. 2001, 66, 348) with diethyl phosphite or diisopropyl phosphite in the presence of a palladium catalyst is widely used within the art.
- Alkylphosphinic acid isopropyl ester or alkylphosphinic acid ethyl ester may be used in the aforementioned procedures to afford the desired alkylphosphinate esters.
- Other methods such as Michael is- Arbuzov reaction (Chem. Rev. 1981, 81, 415) can also be used to introduce the phosphonate group by coupling a benzyl, arylalkyl, or heteroarylalkyl halide/triflate with triethyl phosphite or triisopropyl phosphite.
- Lithiated heteroaryl ring carbon can react with dialklyl chlorophosphate to attach the phosphonate group to the corresponding heteroaryl ring.
- Standard amide bond formation methods can be used to couple amino groups with carboxylic acids or activated derivatives thereof. For example, (i) reactions of an amine with a carboxylic acid in the presence of DCC or EDC according to the known methods (e g . J Org Chem. 1977. 42, 2019); (ii) conversion of a carboxylic group to an acid chloride b> reaction with oxalyl chloride, followed by coupling the acid chloride with an amine in the presence of a base (e g tri ethyl amine or pyridine) in chloroform or DCM (Org Synth., Collect VoI V, 1973, 336); (iii) other known procedures (Tetrahedron Lett 1990. 31. 7119; Tetrahedron Lett 1989, 30, 6917; J Org Chem 1993, 58, 618).
- a base e g tri ethyl amine or pyridine
- Methyl or ethyl ester is deprotected in the presence of sodium hydroxide or lithium hydroxide in a mixture of THF/EtOH/water (e.g., Tetrahedron Lett. 1977, 3529).
- Benzyl ester is removed using hydrogenolysis conditions (e.g., Org. React. 1953. VII, 263).
- R 2 is the group -E 2 -E 3 , wherein E 2 is a direct bond or an alkylene
- the installation of Y' can be accomplished by Stille couplings (J. Am. Chem. Soc. 1984, 106, 4630; Tetrahedron Lett. 1995, 36, 2191), Suzuki couplings (Chem. Rev. 1995, 95, 2457), Friedel-Crafts alkylations (Synlett 1996, 557), or Negishi couplings (Org. Lett., 2003, 5, 423) as described in Scheme 7.
- R 2 is the group - E 1 -E 2 -E 3 , wherein E 1 is S
- E 1 is S
- the installation of S-P 5 can be accomplished by Pd 2 (dba) 3 , CuBr, or CuI catalyzed reactions ⁇ Tetrahedron 2001, 57, 3069; Tetrahedron Lett. 2000, 41, 1283; Synlett 2004,1254; Org. Lett. 2002, 4, 3517), or displacement reactions as described in Scheme 9.
- P 1 is a protecting group such as Ci_ 4 -alkyl
- P 2 is alkyl or cycloalkyl
- P 3 is a leaving group such as F, Cl, Br, I, or triflate
- P 5 is aryl, heteroaryl.
- X' is X or a functional group that can be transformed into X
- Y" is R -R 5 or a functional group that can be transformed into R 2 -R 50
- Yl is arylene, alkylene. heteroarylene, cycloalkylene. or arylalkylene
- Yl' is Yl-R 5 or a functional group that can be transformed into Yl-R 50 .
- Protection and deprotection in the Schemes may be carried out according to the procedures generally known in the art (e.g., T. W. Greene and P. G. M. Wuts, "Protecting Groups in Organic Synthesis", 3 rd edition, John Wiley & Sons, 1999). Deprotection of a Phosphonate or Phosphinate Ester
- Compounds of Formula II wherein R 50 is -P(O)(OH) 2 or -P(O)(OH)P 2 may be prepared from phosphonate or phosphinate esters using the known cleavage methods.
- Silyl halides are generally used to cleave various phosphonate or phosphinate esters and give the desired phosphonic or phosphinic acid upon mild hydrolysis of the resulting phosphonate or phosphinate silyl esters.
- acid scavengers e.g., HMDS
- Such silyl halides include TMSCl (J.Org. Chem. 1963, 28.
- Aryl and benzyl phosphonate or phosphinate esters can be cleaved under hydrogenolysis conditions (Synthesis 1982, 412; J. Med. Chem. 1985, 28, 1208) or metal reduction conditions (J Chem. Soc. 1977, 99, 5188). Electrochemical (J Org. Chem. 1979, 44, 4508) and pyrolysis (Synth. Commun. 1980, 10, 299) conditions have been used to cleave various phosphonate esters.
- Standard amide bond formation methods can be used to couple amino groups with carboxylic acids or activated derivatives thereof. For example, (i) reactions of an amine with a carboxylic acid in the presence of DCC or EDC according to the known methods (e.g., J. Org. Chem. 1977, 42, 2019); (ii) conversion of a carboxylic group to an acid chloride by reaction with oxalyl chloride, followed by coupling the acid chloride with amine in the presence of a base (e.g. triethyl amine or pyridine) in chloroform or DCM (Org. Synth., Collect Vol. V, 1973, 336); (iii) other known procedures (Tetrahedron Lett. 1990, 31, 7119; Tetrahedron Lett. 1989, 30, 6917; J. Org. Chem. 1993, 58, 618).
- Scheme 15 Scheme 15
- esters are well known in the art. Methyl or ethyl ester is deprotected in the presence of sodium hydroxide or lithium hydroxide in a mixture of THF/EtOH/water (e.g., Tetrahedron Lett. 1977, 3529). Benzyl ester is removed using hydrogenolysis condition (e.g., Org. React. 1953, VIL 263).
- hydrogenolysis condition e.g., Org. React. 1953, VIL 263
- R 2 is the group -E -E -, wherein E is arylene, heteroarylene. alkylene, or cycloalkylene
- the installation of Y can be accomplished by Stille couplings (J Am. Chem. Soc. 1984, 106, 4630; Tetrahedron Lett. 1995, 36, 2191), Suzuki couplings (Chem. Rev. 1995, 95, 2457), Friedel-Crafts alkylations (Synlett 1996, 557), or Negishi couplings (Org. Lett., 2003, 5, 423) as described in Scheme 19.
- a phosphonate or phosphinate group can be accomplished according to known procedures.
- Compounds of Formula II. wherein the phosphorous-containing group is directly attached to an arylene or a nitrogen-containing heteroarylene may be prepared by a number of known methods. For example, the coupling reaction of a phenyl bromide (J Org. Chem. 1999. 64, 120), iodide (Phosphorus Sulfur 1997, 130, 59) or triflate (J. Org. Chem. 2001, 66, 348) with diethyl phosphite or diisopropyl phosphite in the presence of a palladium catalyst is widely used within the art.
- Alkylphosphinic acid isopropyl ester or alkylphosphinic acid ethyl ester may be used in the aforementioned procedures to afford the desired alkylphosphinate esters.
- Functionalized arylphosphinates may be prepared according to a known procedure (Tetrahedron Lett. 1996, 37, 1651)
- Compounds of Formula II, wherein the phosphonate is directly attached to an alkylene linker may be prepared by a number of known methods.
- Michaelis- Arbuzov reaction (Chem. Rev. 1981, 81, 415) can also be used to introduce the phosphonate group by coupling an alkyl, benzyl, arylalkyl, or heteroarylalkyl halide/triflate with triethyl phosphite or triisopropyl phosphite.
- H- phosphinic acid can be formed according to literature procedures (Tetrahedron Lett. 1992, 33, 813: J Orgnomet. Chem. 2005, 690, 2388; Tetrahedron 2005, 6L 6315). These H- phosphinic acid derivatives can be alkylated to give the corresponding alkylphosphinates according to known procedures (Synthesis 1985, 896; Synthesis 1986, 240; Phosphorus Sulfur 1996. 775, 255; J. Am. Chem. Soc. 1996, 118, 10168; J Am. Chem. Soc. 2002, 124, 3842).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08827446.9A EP2185570B1 (en) | 2007-08-13 | 2008-08-13 | Novel activators of glucokinase |
BRPI0815557-7A2A BRPI0815557A2 (en) | 2007-08-13 | 2008-08-13 | GLUCKINASE ACTIVATORS |
MX2010001784A MX2010001784A (en) | 2007-08-13 | 2008-08-13 | Novel activators of glucokinase. |
CN200880111311.8A CN101821276B (en) | 2007-08-13 | 2008-08-13 | Novel activators of glucokinase |
JP2010521136A JP5572549B2 (en) | 2007-08-13 | 2008-08-13 | Novel activator of glucokinase |
CA2695583A CA2695583A1 (en) | 2007-08-13 | 2008-08-13 | Novel activators of glucokinase |
US13/115,647 US8940927B2 (en) | 2007-08-13 | 2011-05-25 | Activators of glucokinase |
US14/585,073 US9522926B2 (en) | 2007-08-13 | 2014-12-29 | Activators of glucokinase |
US15/384,226 US10174062B2 (en) | 2007-08-13 | 2016-12-19 | Activators of glucokinase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95552207P | 2007-08-13 | 2007-08-13 | |
US60/955,522 | 2007-08-13 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12673743 A-371-Of-International | 2008-08-13 | ||
US13/115,647 Continuation US8940927B2 (en) | 2007-08-13 | 2011-05-25 | Activators of glucokinase |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009023718A2 true WO2009023718A2 (en) | 2009-02-19 |
WO2009023718A3 WO2009023718A3 (en) | 2009-04-16 |
Family
ID=40351465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/073026 WO2009023718A2 (en) | 2007-08-13 | 2008-08-13 | Novel activators of glucokinase |
Country Status (8)
Country | Link |
---|---|
US (3) | US8940927B2 (en) |
EP (1) | EP2185570B1 (en) |
JP (1) | JP5572549B2 (en) |
CN (2) | CN101821276B (en) |
BR (1) | BRPI0815557A2 (en) |
CA (1) | CA2695583A1 (en) |
MX (1) | MX2010001784A (en) |
WO (1) | WO2009023718A2 (en) |
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009127822A2 (en) * | 2008-04-16 | 2009-10-22 | Biolipox Ab | Bis-aryl compounds for use as medicaments |
WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
WO2011161030A1 (en) | 2010-06-21 | 2011-12-29 | Sanofi | Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators |
WO2012004269A1 (en) | 2010-07-05 | 2012-01-12 | Sanofi | (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals |
WO2012004270A1 (en) | 2010-07-05 | 2012-01-12 | Sanofi | Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament |
WO2012010413A1 (en) | 2010-07-05 | 2012-01-26 | Sanofi | Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
US8604032B2 (en) | 2010-05-21 | 2013-12-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
US8642604B2 (en) | 2006-04-04 | 2014-02-04 | The Regents Of The University Of California | Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents |
US8697709B2 (en) | 2008-10-16 | 2014-04-15 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
US8703777B2 (en) | 2008-01-04 | 2014-04-22 | Intellikine Llc | Certain chemical entities, compositions and methods |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
US8785470B2 (en) | 2011-08-29 | 2014-07-22 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8785454B2 (en) | 2009-05-07 | 2014-07-22 | Intellikine Llc | Heterocyclic compounds and uses thereof |
WO2014112799A1 (en) * | 2013-01-16 | 2014-07-24 | 주식회사유한양행 | Phenoxybenzamide glucokinase activator containing novel heteroaryl and method for preparing same |
US8809349B2 (en) | 2011-01-10 | 2014-08-19 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
US8835420B2 (en) | 2012-07-10 | 2014-09-16 | Takeda Pharmaceutical Company Limited | Azaindole derivatives |
US8901133B2 (en) | 2010-11-10 | 2014-12-02 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8940927B2 (en) | 2007-08-13 | 2015-01-27 | Metabasis Therapeutics, Inc. | Activators of glucokinase |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
US9056877B2 (en) | 2011-07-19 | 2015-06-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9096611B2 (en) | 2008-07-08 | 2015-08-04 | Intellikine Llc | Kinase inhibitors and methods of use |
US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
US9321772B2 (en) | 2011-09-02 | 2016-04-26 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
US9359365B2 (en) | 2013-10-04 | 2016-06-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9359349B2 (en) | 2007-10-04 | 2016-06-07 | Intellikine Llc | Substituted quinazolines as kinase inhibitors |
US9371321B2 (en) | 2014-01-09 | 2016-06-21 | Astrazeneca Ab | Azaindole derivatives |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
US9629843B2 (en) | 2008-07-08 | 2017-04-25 | The Regents Of The University Of California | MTOR modulators and uses thereof |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9775844B2 (en) | 2014-03-19 | 2017-10-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9908908B2 (en) | 2012-08-30 | 2018-03-06 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Tenofovir prodrug and pharmaceutical uses thereof |
US10131668B2 (en) | 2012-09-26 | 2018-11-20 | The Regents Of The University Of California | Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1 |
US10160761B2 (en) | 2015-09-14 | 2018-12-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
US10471082B2 (en) | 2012-10-23 | 2019-11-12 | Georgetown University | Flavivirus protease inhibitors |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11110096B2 (en) | 2014-04-16 | 2021-09-07 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US11147818B2 (en) | 2016-06-24 | 2021-10-19 | Infinity Pharmaceuticals, Inc. | Combination therapies |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104151360B (en) * | 2013-05-14 | 2019-02-22 | 北京美倍他药物研究有限公司 | Phosphoric acid/phosphonate derivative and its medical usage |
EP3140298A1 (en) | 2014-05-07 | 2017-03-15 | Pfizer Inc. | Tropomyosin-related kinase inhibitors |
CN105837599A (en) * | 2015-01-14 | 2016-08-10 | 中国科学院上海药物研究所 | N-substituted-3,5-disubstituted benzamide compound, preparation method and application thereof |
WO2018017910A1 (en) | 2016-07-22 | 2018-01-25 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3524846A (en) | 1967-06-02 | 1970-08-18 | Syntex Corp | Process for the didealkylation of phosphonate esters |
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4026709A (en) | 1973-03-09 | 1977-05-31 | Ciba-Geigy Ag | Color photographic recording material |
US3984432A (en) * | 1973-03-09 | 1976-10-05 | Ciba-Geigy Ag | Color photographic recording material |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
JPS61151199A (en) * | 1984-12-26 | 1986-07-09 | Otsuka Pharmaceut Factory Inc | Carboxylic acid amide derivative |
US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
US5091552A (en) | 1986-06-30 | 1992-02-25 | Board Of Regents, The University Of Texas System | Novel antitumor aldophosphamide analogs |
JPH0651625B2 (en) * | 1986-12-29 | 1994-07-06 | 株式会社大塚製薬工場 | Antihyperlipidemic agent |
US4822780A (en) * | 1987-07-08 | 1989-04-18 | Otsuka Pharmaceutical Factory, Inc. | Carboxamide compounds |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (en) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
CA2083386C (en) | 1990-06-13 | 1999-02-16 | Arnold Glazier | Phosphorous prodrugs |
US5157027A (en) | 1991-05-13 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Bisphosphonate squalene synthetase inhibitors and method |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
CA2126601A1 (en) | 1993-06-29 | 1994-12-30 | Mitsubishi Chemical Corporation | Phosphonate-nucleotide ester derivatives |
IT1270594B (en) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN |
US5780058A (en) | 1995-07-21 | 1998-07-14 | Alza Corporation | Oral delivery of discrete units |
US6132420A (en) | 1996-02-02 | 2000-10-17 | Alza Corporation | Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems |
MY125849A (en) | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems |
EP1041975B1 (en) | 1997-12-22 | 2002-09-04 | Alza Corporation | Rate controlling membranes for controlled drug delivery devices |
JP4173635B2 (en) | 1997-12-29 | 2008-10-29 | インターシア セラピューティクス,インコーポレイティド | Permeation supply apparatus having membrane plug holding mechanism |
CA2316887C (en) | 1997-12-31 | 2008-04-08 | Alza Corporation | Osmotic drug delivery monitoring system and method |
US6245357B1 (en) | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
US6365185B1 (en) | 1998-03-26 | 2002-04-02 | University Of Cincinnati | Self-destructing, controlled release peroral drug delivery system |
BR9913532A (en) * | 1998-09-09 | 2001-10-02 | Metabasis Therapeutics Inc | New heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
NZ511465A (en) | 1998-11-02 | 2003-10-31 | Alza Corp | Controlled delivery of active agents |
US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
JP4979866B2 (en) | 1999-09-08 | 2012-07-18 | リガンド・ファーマシューティカルズ・インコーポレイテッド | Prodrug for drug delivery specific to the liver |
IL151248A0 (en) * | 2000-03-08 | 2003-04-10 | Metabasis Therapeutics Inc | Novel aryl fructose-1,6-bisphosphatase inhibitors |
AU2002309083A1 (en) * | 2001-03-30 | 2002-10-15 | Biocrine Ab | Method for identifying drugs for the treatment of type ii diabetes |
CN101712657A (en) * | 2003-02-26 | 2010-05-26 | 万有制药株式会社 | heteroarylcarbamoylbenzene derivative |
GB0328178D0 (en) * | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Compounds |
JP4931598B2 (en) | 2004-10-13 | 2012-05-16 | 独立行政法人国立がん研究センター | Intestinal polyp inhibitor |
US7910747B2 (en) * | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
WO2008154563A1 (en) | 2007-06-11 | 2008-12-18 | Bristol-Myers Squibb Company | 1, 3 - dihydroxy substituted phenylamide glucokinase activators |
MX2010001784A (en) | 2007-08-13 | 2010-03-15 | Metabasis Therapeutics Inc | Novel activators of glucokinase. |
-
2008
- 2008-08-13 MX MX2010001784A patent/MX2010001784A/en not_active Application Discontinuation
- 2008-08-13 BR BRPI0815557-7A2A patent/BRPI0815557A2/en not_active IP Right Cessation
- 2008-08-13 EP EP08827446.9A patent/EP2185570B1/en active Active
- 2008-08-13 CN CN200880111311.8A patent/CN101821276B/en not_active Expired - Fee Related
- 2008-08-13 CN CN201610711385.1A patent/CN106279283A/en active Pending
- 2008-08-13 WO PCT/US2008/073026 patent/WO2009023718A2/en active Application Filing
- 2008-08-13 JP JP2010521136A patent/JP5572549B2/en not_active Expired - Fee Related
- 2008-08-13 CA CA2695583A patent/CA2695583A1/en not_active Abandoned
-
2011
- 2011-05-25 US US13/115,647 patent/US8940927B2/en not_active Expired - Fee Related
-
2014
- 2014-12-29 US US14/585,073 patent/US9522926B2/en active Active
-
2016
- 2016-12-19 US US15/384,226 patent/US10174062B2/en not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
None |
See also references of EP2185570A4 |
Cited By (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
US8642604B2 (en) | 2006-04-04 | 2014-02-04 | The Regents Of The University Of California | Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents |
US9493467B2 (en) | 2006-04-04 | 2016-11-15 | The Regents Of The University Of California | PI3 kinase antagonists |
US10174062B2 (en) | 2007-08-13 | 2019-01-08 | Metabasis Therapeutics, Inc. | Activators of glucokinase |
US8940927B2 (en) | 2007-08-13 | 2015-01-27 | Metabasis Therapeutics, Inc. | Activators of glucokinase |
US9522926B2 (en) | 2007-08-13 | 2016-12-20 | Metabasis Therapeutics, Inc. | Activators of glucokinase |
US9359349B2 (en) | 2007-10-04 | 2016-06-07 | Intellikine Llc | Substituted quinazolines as kinase inhibitors |
US9216982B2 (en) | 2008-01-04 | 2015-12-22 | Intellikine Llc | Certain chemical entities, compositions and methods |
US11433065B2 (en) | 2008-01-04 | 2022-09-06 | Intellikine Llc | Certain chemical entities, compositions and methods |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US8785456B2 (en) | 2008-01-04 | 2014-07-22 | Intellikine Llc | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US9655892B2 (en) | 2008-01-04 | 2017-05-23 | Intellikine Llc | Certain chemical entities, compositions and methods |
US9822131B2 (en) | 2008-01-04 | 2017-11-21 | Intellikine Llc | Certain chemical entities, compositions and methods |
US8703777B2 (en) | 2008-01-04 | 2014-04-22 | Intellikine Llc | Certain chemical entities, compositions and methods |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
US9637492B2 (en) | 2008-03-14 | 2017-05-02 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
WO2009127822A3 (en) * | 2008-04-16 | 2010-03-11 | Biolipox Ab | Bis-aryl compounds for use as medicaments |
WO2009127822A2 (en) * | 2008-04-16 | 2009-10-22 | Biolipox Ab | Bis-aryl compounds for use as medicaments |
US9096611B2 (en) | 2008-07-08 | 2015-08-04 | Intellikine Llc | Kinase inhibitors and methods of use |
US9828378B2 (en) | 2008-07-08 | 2017-11-28 | Intellikine Llc | Kinase inhibitors and methods of use |
US9629843B2 (en) | 2008-07-08 | 2017-04-25 | The Regents Of The University Of California | MTOR modulators and uses thereof |
US9790228B2 (en) | 2008-09-26 | 2017-10-17 | Intellikine Llc | Heterocyclic kinase inhibitors |
US9296742B2 (en) | 2008-09-26 | 2016-03-29 | Intellikine Llc | Heterocyclic kinase inhibitors |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
US8697709B2 (en) | 2008-10-16 | 2014-04-15 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
US8785454B2 (en) | 2009-05-07 | 2014-07-22 | Intellikine Llc | Heterocyclic compounds and uses thereof |
US9315505B2 (en) | 2009-05-07 | 2016-04-19 | Intellikine Llc | Heterocyclic compounds and uses thereof |
US9522146B2 (en) | 2009-07-15 | 2016-12-20 | Intellikine Llc | Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof |
US8569323B2 (en) | 2009-07-15 | 2013-10-29 | Intellikine, Llc | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof |
US9206182B2 (en) | 2009-07-15 | 2015-12-08 | Intellikine Llc | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof |
US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
US9738644B2 (en) | 2010-05-21 | 2017-08-22 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
US9181221B2 (en) | 2010-05-21 | 2015-11-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
US8604032B2 (en) | 2010-05-21 | 2013-12-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
WO2011161030A1 (en) | 2010-06-21 | 2011-12-29 | Sanofi | Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators |
WO2012004270A1 (en) | 2010-07-05 | 2012-01-12 | Sanofi | Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament |
WO2012004269A1 (en) | 2010-07-05 | 2012-01-12 | Sanofi | (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals |
WO2012010413A1 (en) | 2010-07-05 | 2012-01-26 | Sanofi | Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament |
US8901133B2 (en) | 2010-11-10 | 2014-12-02 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9388183B2 (en) | 2010-11-10 | 2016-07-12 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9840505B2 (en) | 2011-01-10 | 2017-12-12 | Infinity Pharmaceuticals, Inc. | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof |
US11312718B2 (en) | 2011-01-10 | 2022-04-26 | Infinity Pharmaceuticals, Inc. | Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one |
US10550122B2 (en) | 2011-01-10 | 2020-02-04 | Infinity Pharmaceuticals, Inc. | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof |
USRE46621E1 (en) | 2011-01-10 | 2017-12-05 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US9290497B2 (en) | 2011-01-10 | 2016-03-22 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US8809349B2 (en) | 2011-01-10 | 2014-08-19 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
US9605003B2 (en) | 2011-07-19 | 2017-03-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9718815B2 (en) | 2011-07-19 | 2017-08-01 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9056877B2 (en) | 2011-07-19 | 2015-06-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8785470B2 (en) | 2011-08-29 | 2014-07-22 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9546180B2 (en) | 2011-08-29 | 2017-01-17 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9115141B2 (en) | 2011-08-29 | 2015-08-25 | Infinity Pharmaceuticals, Inc. | Substituted isoquinolinones and methods of treatment thereof |
US9321772B2 (en) | 2011-09-02 | 2016-04-26 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
US9895373B2 (en) | 2011-09-02 | 2018-02-20 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9255108B2 (en) | 2012-04-10 | 2016-02-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
US9527847B2 (en) | 2012-06-25 | 2016-12-27 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
US8835420B2 (en) | 2012-07-10 | 2014-09-16 | Takeda Pharmaceutical Company Limited | Azaindole derivatives |
US9908908B2 (en) | 2012-08-30 | 2018-03-06 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Tenofovir prodrug and pharmaceutical uses thereof |
US11613544B2 (en) | 2012-09-26 | 2023-03-28 | The Regents Of The University Of California | Substituted imidazo[1,5-a]pyrazines for modulation of IRE1 |
US10822340B2 (en) | 2012-09-26 | 2020-11-03 | The Regents Of The University Of California | Substituted imidazolopyrazine compounds and methods of using same |
US10131668B2 (en) | 2012-09-26 | 2018-11-20 | The Regents Of The University Of California | Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1 |
US10471082B2 (en) | 2012-10-23 | 2019-11-12 | Georgetown University | Flavivirus protease inhibitors |
WO2014112799A1 (en) * | 2013-01-16 | 2014-07-24 | 주식회사유한양행 | Phenoxybenzamide glucokinase activator containing novel heteroaryl and method for preparing same |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
US9828377B2 (en) | 2013-10-04 | 2017-11-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10329299B2 (en) | 2013-10-04 | 2019-06-25 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9359365B2 (en) | 2013-10-04 | 2016-06-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9371321B2 (en) | 2014-01-09 | 2016-06-21 | Astrazeneca Ab | Azaindole derivatives |
US9775844B2 (en) | 2014-03-19 | 2017-10-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10675286B2 (en) | 2014-03-19 | 2020-06-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11541059B2 (en) | 2014-03-19 | 2023-01-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11110096B2 (en) | 2014-04-16 | 2021-09-07 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US11944631B2 (en) | 2014-04-16 | 2024-04-02 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US10941162B2 (en) | 2014-10-03 | 2021-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10253047B2 (en) | 2014-10-03 | 2019-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
US11247995B2 (en) | 2015-09-14 | 2022-02-15 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
US10160761B2 (en) | 2015-09-14 | 2018-12-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
US11939333B2 (en) | 2015-09-14 | 2024-03-26 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11147818B2 (en) | 2016-06-24 | 2021-10-19 | Infinity Pharmaceuticals, Inc. | Combination therapies |
Also Published As
Publication number | Publication date |
---|---|
EP2185570A4 (en) | 2011-02-09 |
EP2185570B1 (en) | 2014-03-19 |
JP5572549B2 (en) | 2014-08-13 |
US9522926B2 (en) | 2016-12-20 |
MX2010001784A (en) | 2010-03-15 |
CN106279283A (en) | 2017-01-04 |
US10174062B2 (en) | 2019-01-08 |
US20170096440A1 (en) | 2017-04-06 |
CN101821276A (en) | 2010-09-01 |
CN101821276B (en) | 2016-08-31 |
US20150119365A1 (en) | 2015-04-30 |
US8940927B2 (en) | 2015-01-27 |
WO2009023718A3 (en) | 2009-04-16 |
CA2695583A1 (en) | 2009-02-19 |
JP2010536773A (en) | 2010-12-02 |
EP2185570A2 (en) | 2010-05-19 |
US20110294758A1 (en) | 2011-12-01 |
BRPI0815557A2 (en) | 2015-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10174062B2 (en) | Activators of glucokinase | |
EP1265907B1 (en) | Novel aryl fructose-1,6-bisphosphatase inhibitors | |
KR100818845B1 (en) | Novel Heteroaromatic Inhibitors of Fructose 1,6-Bisphosphatase | |
CA2894112C (en) | Novel antagonists of the glucagon receptor | |
WO2008019309A1 (en) | Novel inhibitors of fructose 1,6-bisphosphatase | |
EP0882730B1 (en) | Phosphonic acid diester derivatives | |
WO1998039342A1 (en) | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase | |
JP2003519154A (en) | Novel bisamidate phosphonate prodrug | |
WO1998039344A1 (en) | Novel purine inhibitors of fructose-1,6-bisphosphatase | |
AU2001245532A1 (en) | Novel aryl fructose-1,6-bisphosphatase inhibitors | |
US20070099851A1 (en) | Stable analogues of ribose-1-phosphate and methods for treating diabetes and other metabolic disorders | |
KR20060028632A (en) | Anti-inflammatory phosphonate compounds | |
KR20060061292A (en) | Phosphonate compounds having immuno-modulatory activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880111311.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08827446 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2695583 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2010/001784 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010521136 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1532/DELNP/2010 Country of ref document: IN Ref document number: 2008827446 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0815557 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100212 |